

**IN THE UNITED STATES DISTRICT COURT
FOR THE WESTERN DISTRICT OF PENNSYLVANIA**

HIGHMARK INC.,	)	
	)	
	)	
<i>Plaintiff,</i>	)	Case No. _____
	)	
v.	)	
	)	
BROMEDICON, LLC and HALOMD,	)	
LLC,	)	
	)	
<i>Defendants.</i>	)	
	)	

COMPLAINT

Plaintiff, Highmark Inc. (“Plaintiff” or “Highmark”), by and through its undersigned counsel, hereby submits this Complaint against Defendants Bromedicon, LLC (“Bromedicon”) and HaloMD, LLC (“HaloMD”) (collectively, “Defendants”) and in support thereof, alleges as follows:

INTRODUCTION

1. Highmark brings this action to vacate hundreds of independent dispute resolution (“IDR”) insurance payment determinations involving millions of dollars that Defendants Bromedicon and HaloMD procured through fraud, undue means, and misrepresentations of fact presented to certified IDR entities (“IDREs”), and that IDREs issued in excess of their authority over disputes that were never validly subject to the federal No Surprises Act (“NSA”) IDR process. In addition, and in the alternative, Highmark asserts tort, statutory, and equitable claims for Defendants’ independent misconduct, both because that intentional and fraudulent misconduct caused independent injuries to Highmark that are not duplicative of vacatur and because, if the

Court concludes (as it should) that some or all of the challenged disputes were inarbitrable from the outset or otherwise outside the NSA’s judicial review framework, those claims provide an independent basis for relief.

2. As set forth below, Defendants have weaponized the federal NSA, 42 U.S.C. § 300gg-111—a statute enacted to protect commercially insured patients from surprise out-of-network medical bills—by transforming the IDR process into a vehicle for fraud and financial gain. Defendants’ scheme is not a good faith attempt to obtain fair reimbursement. It is a deliberate effort to wrongfully extract inflated payments from Highmark through, among other things: (i) the intentional and knowing submission of hundreds of categorically ineligible disputes, including disputes barred by the NSA’s 90-day-cooling off period, and (ii) material misrepresentations to IDREs that the NSA’s “blind,” non-adversarial procedures prevented Highmark from identifying or meaningfully rebutting in real time.

3. The NSA established the IDR process to resolve limited categories of surprise billing disputes between health plans and out-of-network providers, thereby protecting patients who unknowingly receive out-of-network care or require emergency service from being saddled with excessive balance bills reflecting the gap between a provider’s charges and the plan’s reimbursement. The IDR process is strictly limited to “qualified IDR items or services” that satisfy defined eligibility criteria, including, among other requirements, that no prior IDR determination has been issued for the same items or services between the same provider and payor within the preceding 90 calendar days (the “90-day cooling off period”).

4. In repeated knowing and intentional violation of this eligibility requirement, Defendants have engaged in a pattern of obtaining IDR payment determinations for particular procedure codes and then, *often the same day or the very next day*, initiating new IDR disputes

against Highmark involving those identical codes. Defendants do so with full knowledge that such disputes are ineligible for the IDR process under the 90-day cooling-off period.

5. Moreover, Highmark has obtained IDR submission packages from certain IDREs and, *for the first time*, discovered that Defendants made material misrepresentations in their “blind” IDR submissions. Highmark could not have identified these misstatements during the IDR process because the NSA requires a “blind” proceeding in which each party submits its final offer and supporting materials without the right or ability to see the opposing party’s submission. These misrepresentations include, among others: (a) the selective citation of misleading, cherry-picked reimbursement data from other health plans—*not Highmark*—and from different time periods and geographic regions in purported support of the qualifying payment amount (“QPA”); and (b) false representations to IDREs that Highmark failed to engage in negotiations regarding in-network rates, including the submission of *supposed correspondence that Highmark never received*. In fact, Highmark did engage in communications aimed at establishing reasonable in-network reimbursement rates and contractual agreements with Bromedicon. Despite those efforts, Bromedicon failed to engage in meaningful dialogue regarding reimbursement terms and network participation, frustrating the parties’ ability to reach an agreement and undermining the collaborative negotiation process contemplated by the NSA. Defendants advanced these misrepresentations to mislead IDREs and secure inflated payment determinations, many of which were not eligible for IDR in the first place.

6. As a direct and proximate result of Defendants’ fraudulent conduct, Highmark has suffered and continues to suffer substantial damages, including improper IDR payment determinations, administrative and IDRE fees, and the diversion of significant resources to address ineligible and fraudulently submitted IDR disputes. While abuse of the IDR process by providers

and their billing agents has been well documented and has added at least \$5 billion to overall health system costs since its inception, Defendants' fraud goes further, threatening the affordability and sustainability of health care coverage for Highmark's members and the self-insured employer groups—including public school districts, state and local governmental entities, and labor unions—whose benefits Highmark administers across Pennsylvania and nationwide.¹

7. Highmark brings this action to put an end to Defendants' exploitation of the IDR process and their deliberate scheme to defraud Highmark through false eligibility attestations and intentional misrepresentations, which Highmark was unable to discover or challenge during the IDR proceedings themselves.

PARTIES

8. Plaintiff Highmark is a not-for-profit health plan and professional health services plan corporation which operates and has its principal place of business in Allegheny County, Pennsylvania.

9. Defendant Bromedicon is a Delaware limited liability company that provides neuromonitoring services to members of health plans administered by Highmark. Bromedicon maintains its principal place of business in West Conshohocken, Pennsylvania, and regularly transacts business in the Commonwealth of Pennsylvania. Upon information and belief, Bromedicon is a subsidiary of Medsurant Health, an affiliate of MPOWERHealth Practice Management, LLC ("MPOWERHealth").²

¹ See Jack Hoadley, Kennah Watts, Katie Keith, & Ellie DeGarmo, *The No Surprises Act IDR Process: An Early Look At 2025 Data*, HEALTH AFFAIRS (Mar. 20, 2026), <https://www.healthaffairs.org/content/forefront/no-surprises-act-idr-process-early-look-2025-data>.

² See <https://medsuranthealth.com/about-medsurant/our-practices.html> (last visited Apr. 15, 2026). Upon information and belief, MPOWERHealth operates and/or controls a network of provider entities that furnish out-of-network services, including Bromedicon.

10. Defendant HaloMD is a Delaware limited liability company with a principal place of business in Addison, Texas. HaloMD is a third-party billing and dispute-resolution company that administers open negotiations and IDR proceedings on behalf of out-of-network healthcare providers, including Bromedicon. Upon information and belief, HaloMD is owned and controlled by Alla LaRoque, its founder and President. Alla LaRoque is married to Scott LaRoque, the founder and Chief Executive Officer of MPOWERHealth,³ who also holds ownership interests in HaloMD through affiliated entities.⁴ Although founded only in 2022, HaloMD has rapidly become one of the largest participants in—and, as alleged herein, one of the most prolific abusers of—the federal NSA IDR process. Public analyses of data published by the Centers for Medicare & Medicaid Services (“CMS”), the federal agency responsible for administering and reporting on the IDR program, identify HaloMD as one of the largest initiating parties in the federal IDR system, responsible for approximately 10% of all disputes initiated during Q2 2024 and ranking among the highest-volume filers nationwide.

11. Upon information and belief, Bromedicon retained HaloMD to engage in the NSA’s open negotiation process, initiate IDRs, and otherwise pursue payment disputes against Highmark on Bromedicon’s behalf. In doing so, HaloMD acted as Bromedicon’s agent and co-conspirator in the fraudulent scheme alleged herein.

³ Alla LaRoque sits on the board of MPOWERHealth and previously served as MPOWERHealth’s Chief Operating Officer. *See* <https://mpowerhealth.com/board-members/#>.

⁴ According to filings with the Texas Secretary of State, HaloMD has two members. The first member of HaloMD is LFF Holdings Groups Ltd Co (“LFF”). LFF is a Texas limited liability company with Scott LaRoque as its sole member. The second member of HaloMD is Scalla Investments, L.L.C. (“Scalla Investments”). Scalla Investments is a Texas limited liability company with Scott LaRoque and Alla LaRoque as its sole members.

JURISDICTION AND VENUE

12. This Court has federal question jurisdiction under 28 U.S.C. § 1331 because Count I arises under the NSA, which expressly provides for judicial review of IDR payment determinations in the limited circumstances set forth in Section 10(a) of the Federal Arbitration Act (“FAA”). *See* 42 U.S.C. § 300gg-111(c)(5)(E)(i)(II) (incorporating 9 U.S.C. § 10(a)(1)–(4)). The NSA further provides that IDR payment determinations “shall be binding upon the parties involved, in the absence of a fraudulent claim or evidence of misrepresentation of facts presented to the IDR entity involved regarding such claim.” *Id.* § 300gg-111(c)(5)(E)(i)(I).]

13. Highmark seeks vacatur of the IDR payment determinations specified in Exhibit A⁵ on the grounds that Defendants procured them through fraudulent claims, misrepresentations of facts, fraud, and undue means, and/or because the IDREs exceeded their authority by issuing determinations over disputes that were not validly subject to the NSA IDR process.

14. This Court also has supplemental jurisdiction under 28 U.S.C. § 1367 over Highmark’s related tort, statutory, declaratory, and equitable claims because those claims arise from the same transactions and occurrences as Count I, including the same IDR submissions, challenged determinations, alleged misrepresentations, payments, administrative fees, and course of conduct.

15. Highmark pleads its tort, statutory, declaratory, and equitable claims in addition to, and in the alternative to, Count I. These claims arise from Defendants’ independent misconduct—

⁵ The IDR payment determinations for which Highmark currently seeks vacatur are identified in Exhibit A based on Highmark’s reasonable pre-suit investigation and information presently available to it. Because the challenged IDR submissions and determinations involve a high volume of records and information uniquely within Defendants’ possession or control, Highmark continues to review the relevant data and reserves the right to supplement, amend, or conform Exhibit A and its requested relief to the evidence developed through discovery, expert analysis, and further investigation.

including fraud and related torts—through which Defendants intentionally submitted disputes they knew to be ineligible for the NSA IDR process, supported by false eligibility attestations, sham correspondence, and material misrepresentations in “blind” submissions to IDREs. These claims are pleaded in addition to Count I because they seek redress for distinct injuries. They are pleaded in the alternative because, if the Court determines that some or all of the challenged disputes were categorically ineligible for the NSA IDR process, were inarbitrable from the outset, or otherwise fall outside the NSA’s judicial-review provision, then the NSA does not bar Highmark from pursuing independent tort, statutory, declaratory, and equitable remedies for Defendants’ misconduct and for determinations that were never valid, binding NSA IDR determinations in the first place.

16. Venue is proper in this District pursuant to 28 U.S.C. § 1391(b) because: (i) a substantial part of the events or omissions giving rise to the claims occurred in, and were directed toward, this District; and (ii) Highmark is headquartered in this District and has suffered injury here.

FACTUAL BACKGROUND

I. Highmark Is a Community-Focused Health Plan

17. Highmark is a nonprofit organization that operates as a Blue Cross Blue Shield licensee in Pennsylvania, Delaware, New York, and West Virginia, serving over seven million people. Highmark offers a broad range of high-quality, accessible and affordable health plans – including individual, employer-sponsored, Medicare, and Medicaid options – with an emphasis on providing affordable rates for members, including those with low incomes or who have difficulty getting insurance. As a regional, nonprofit payor, Highmark is community-driven and often seeks

strategic partnerships with its largest providers to improve the health and well-being of its members and their communities.

18. A significant portion of Highmark’s business is administrative services only (“ASO”), where Highmark acts as a third-party administrator for self-insured groups and has obligations to pursue recovery of overpayments to providers. These self-insured groups include state and local government entities, public school districts, labor unions, and mid-sized to large private employers, all of which bear the full cost of healthcare claims and immediately absorb the impact of any increase in provider rates. The remainder of Highmark’s commercial enrollment is fully-insured business where Highmark is responsible for payment of healthcare costs and managing the risk for a pool of insureds. For this business, insured individuals are impacted by increased care costs in the form of higher health insurance premiums and cost-sharing amounts.

II. The No Surprises Act and the IDR Process

19. Effective January 1, 2022, the NSA banned surprise billing for three categories of out-of-network care: (1) emergency services; (2) non-emergency services at in-network facilities; and (3) air ambulance services. *See* 42 U.S.C. §§ 300gg-131, 300gg-132, 300gg-135. Congress enacted the NSA with a clear purpose: to protect patients from unexpected and often financially devastating medical bills while establishing an independent system to resolve payment disputes in a manner that is “fair to both providers and plans that also does not increase aggregate healthcare system costs.”⁶ *See* Ban Surprise Billing Act, H.R. Rep. No. 116-615 (2020), at 47, 52–53. Congress recognized that certain out-of-network providers held “substantial market power” and

⁶ *See also* Lawson Mansell & Sage Mehta, *New data shows No Surprises Act arbitration is growing healthcare waste*, NISKANEN CENTER (June 18, 2025), <https://www.niskanencenter.org/new-data-shows-no-surprises-act-arbitration-is-growing-healthcare-waste/>; *Evidence on Surprise Billing: Protecting Consumers with the No Surprises Act*, Issue Brief No. HP-2021-24, Off. of the Ass’t Sec’y for Planning & Evaluation, U.S. Dep’t of Health & Human Servs. (Nov. 22, 2021), <http://resource.nlm.nih.gov/9918539088506676>.

“face[d] highly inelastic demands for their services because patients lack[ed] the ability to meaningfully choose or refuse care,” enabling such providers to “charge amounts for their services that . . . result[] in compensation far above what is needed to sustain their practice.” *Id.* at 53. Congress further understood that patients, particularly in emergency or facility-based settings, are often unable to avoid or even anticipate out-of-network care, leaving them uniquely vulnerable to these practices. *Id.* Congress noted that this “market failure” was having “devastating financial impacts on Americans and their ability to afford needed health care.” *Id.* at 52-53.

20. When a health plan like Highmark receives a claim for out-of-network services subject to the NSA, the health plan makes an initial payment or issues a notice of denial of payment within 30 days. *See* 42 U.S.C. § 300gg-111(a)(1)(C)(iv)(I). If the provider is dissatisfied with the initial payment, the provider or its designee may initiate open negotiations with the health plan by providing formal written notice within 30 business days of the initial payment or notice of denial. 42 U.S.C. § 300gg-111(c)(1)(A).

21. After initiating open negotiations, the provider must attempt in good faith to negotiate a resolution with the health plan over a 30-business-day open negotiations period. If the open negotiations do not result in a determination of an amount of payment, the provider may then initiate the IDR process within four business days. *See* 42 U.S.C. § 300gg-111(c)(1)(B); 45 C.F.R. § 149.510(b)(2)(i).

22. The IDR process is only available for a “qualified IDR item or service” that meets strict statutory and regulatory criteria. To be eligible, the following conditions must, among others, be satisfied: (a) the underlying services fall within the NSA’s scope; (b) the services involve a patient with health care coverage subject to the NSA; (c) no specified state surprise billing law applies; (d) the underlying services were covered by the patient’s health benefit plan; (e) the patient

did not waive the NSA's balance billing protections; (f) the provider initiated and exhausted open negotiations; (g) the provider initiated IDR within 4 business days after open negotiations were exhausted; and (h) the provider has not had a previous IDR determination on the same services and against the same payor in the previous 90 calendar days. 42 U.S.C. § 300gg-111(c)(1)(B); 45 C.F.R. § 149.510(a)(2)(xi), (b)(2).

III. The 90-Day Cooling-Off Period

23. The requirement that a provider not have had a previous IDR determination on the same services and against the same payor in the previous 90 calendar days — commonly referred to as the “90-day cooling-off period” — is a critical gatekeeping provision of the NSA.

24. The 90-day cooling-off period ensures that the IDR process is used for the bona fide resolution of discrete billing disputes rather than as a mechanism for providers to serially relitigate rate determinations by flooding the system with duplicative disputes. Congress enacted this provision to incentivize health care providers and payors to resolve their differences amongst themselves, consistent with the NSA's purpose of creating a streamlined process.

25. Under 45 C.F.R. § 149.510(c)(3)(i), following an IDR determination involving a particular provider and a particular health plan with respect to the same or similar item or service, neither party may submit a new IDR claim involving the same or similar item or service against the same party for 90 calendar days following the determination.

IV. The IDR Process Is a Blind Proceeding

26. The NSA's IDR payment determination process resembles a baseball-style arbitration. The provider and health plan each submit an offer, and the IDRE selects one party's offer as the out-of-network rate. 42 U.S.C. § 300gg-111(c)(5)(B).

27. In making its determination, the IDRE must consider the QPA—generally the plan’s median in-network rate for the same service in the same geographic area—and several “additional circumstances,” such as the training, experience, and quality of the provider, its market share, and the acuity of the patient. 42 U.S.C. § 300gg-111(c)(5)(C).


28. The IDR process is a blind proceeding: each party submits its final offer and supporting evidence without the right or ability to see the other party’s submission. There is no mechanism for discovery, cross-examination, or adversarial testing of the opposing party’s representations to the IDRE.

29. The blind nature of the process means that a party to an IDR proceeding has no ability during the proceeding itself to identify, challenge, or rebut misstatements or false evidence submitted by the opposing party in its IDR submission package. Nor does the statute or implementing regulations provide any right for a party to obtain or review the opposing party’s submission during the proceeding. At most, a party may learn what the opposing side submitted only after the IDRE has already rendered its payment determination—and even then, only if the IDRE elects to share that information. As a result, any such disclosure is unusual, and discretionary rather than guaranteed, and in most cases a party may never obtain access to the materials on which the determination was based.

V. The IDR Portal Requires Attestations of Eligibility

30. Parties must initiate the IDR process online through a federal “IDR Portal.” The website for submissions is <https://nsa-idr.cms.gov/paymentdisputes/s/>. The portal is specifically designed to guide initiating parties through eligibility requirements and to prevent the submission of ineligible disputes.

31. At the outset, before an initiating party can begin completing the Notice of IDR Initiation Form, the portal displays a prominent warning in a blue box stating: “*Disputing parties will generally have 4 business days from the conclusion of their open negotiation period to submit a Notice of IDR Initiation, unless the dispute qualifies for an exception, **such as the dispute being subject to the 90-day cooling off period**, the dispute having received prior approval for an extension, or a certified IDR entity has requested the party to resubmit the dispute.*” This warning alerts users to both timing requirements and potential disqualifying conditions, including the 90-day cooling off period.



32. Before proceeding, the initiating party must agree to the portal’s terms and conditions and complete a series of “Qualification Questions.” The terms and conditions include a notice that the initiating party must submit an “[a]ttestation that qualified IDR items or services are within the scope of the Federal IDR process.”

Along with the general information you'll need to start your Federal IDR dispute process, provide:

- Information to identify the qualified IDR items or services (and whether they are designated as batched or bundled items or services)
- Dates and location of qualified IDR items or services
- Type of qualified IDR items or services such as emergency services and post-stabilization services
- Codes for corresponding service and place-of-service
- Attestation that qualified IDR items or services are within the scope of the Federal IDR process
- Your preferred certified IDR entity

33. These questions are designed to assess whether the dispute meets the statutory and regulatory criteria for IDR eligibility. If the responses indicate that the dispute is ineligible—for example, because it falls within the 90-day cooling off period—the portal generates an alert and prevents the user from continuing.

34. Even after agreeing to the terms and conditions, the first page of the Notice of IDR Initiation Form reiterates that disputes falling within the 90-day cooling off period are ineligible for IDR. Thus, the portal provides repeated, explicit notice of this limitation before any submission is completed.




Disputing parties will generally have **4 business days** from the conclusion of their open negotiation period to submit a Notice of IDR Initiation, unless the dispute qualifies for an exception, such as the dispute being subject to the 90-day cooling off period, the dispute having received prior approval for an extension, or a certified IDR entity has requested the party to resubmit the dispute.

IMPORTANT: The administrative fee is \$115.00.

NOTE: Once you complete the Notice of IDR Initiation, download a copy and send the Notice of IDR Initiation PDF to the Non-Initiating Party.

REMINDER: You must complete and submit the form in a single session. For security reasons and protection of personal data, your session will time out after 60 minutes of inactivity.

35. At the conclusion of this process, the submitting party must attest, via electronic signature, that the **“item(s) and/or service(s) at issue are qualified item(s) and/or service(s) within the scope of the Federal IDR process.”** A copy of the completed Notice of IDR Initiation, including this attestation, is then provided to the non-initiating party, the IDRE, and the federal Departments.



☒ I, the undersigned initiating party (or representative of the initiating party), attest that to the best of my knowledge the preferred certified IDR entity does not have a disqualifying conflict of interest and that the item(s) and/or service(s) at issue are qualified item(s) and/or service(s) within the scope of the Federal IDR process.

* Initiating party (or representative of the initiating party): * Date:

36. At multiple stages throughout the portal workflow—from initial warnings, to qualification screening, to final attestation—the initiating party is required to acknowledge and affirm compliance with IDR eligibility requirements. By the time a dispute is submitted, the initiating party has been repeatedly notified of, and has affirmatively represented compliance with, the governing limitations of the IDR process.

37. The notice and attestation requirements do not end with submission of a dispute. When an IDRE issues a payment determination, it provides the parties with a written decision that expressly reiterates the 90-day cooling-off period. Specifically, the IDRE notifies the initiating party that it may not submit a subsequent dispute involving the same or similar item or service against the same opposing party—here, Highmark—within 90 days. The determination further identifies the date on which the cooling off period expires, thereby providing clear, individualized guidance as to when a new dispute may be filed.

The party that initiated the Federal IDR Process may not submit a subsequent Notice of IDR Initiation involving the same other party with respect to a claim for the same or similar item or service that was the subject of this dispute during the 90-calendar-day suspension period following the date of this email, also referred to as the “cooling off” period.

If the initiating party was a provider, the provider is identified by the National Provider Identifier (NPI) or Taxpayer Identification Number (TIN). During the cooling off period, the provider may not submit a subsequent Notice of IDR Initiation involving the same non-initiating party with respect to a claim billed under the same NPI or TIN for the same or similar item or service.

The initiating party with respect to dispute number DISP-1851702 was BROMEDICON, LLC. The initiating party’s NPI is 1003321316 and TIN is 364875473. The non-initiating party was BCBS PA HIGHMARK. The 90-calendar day cooling off period begins on November 22, 2024 . Please retain this information for your records.

38. These post-determination notices are clear and explicit. They leave no ambiguity as to the applicability or duration of the 90-day cooling-off period. Despite receiving these repeated, individualized warnings—including the precise date on which new disputes would become eligible—Defendants nevertheless submitted hundreds of disputes that fell within the prohibited 90-day period.

VI. Defendants’ Fraudulent Scheme

A. Knowing and Intentional Violation of the 90-Day Cooling-Off Period

39. Defendants have engaged in a deliberate and systematic scheme to exploit the IDR process by knowingly initiating IDR disputes that are ineligible under the NSA’s 90-day cooling-off period.

40. The NSA expressly prohibits providers from initiating IDR proceedings for the same item or service against the same payor within 90 days of a prior IDR determination. Each IDR determination provides explicit notice of this restriction, ensuring that providers and their representatives, like Defendants, are aware of the prohibition and the applicable timeframe before submitting additional disputes.

41. Despite this clear rule and repeated notice, Defendants routinely initiated new IDR disputes for the same procedure codes within the 90-day cooling-off period—often within days of receiving an IDR determination.

42. At the same time, Highmark was inundated with hundreds of IDR disputes involving multiple providers and procedure codes, while Defendants alone controlled the decision to initiate each dispute. Despite being in the unique position to refrain from submitting ineligible disputes, Defendants instead chose to engage in a pattern of serial, improper filings in violation of the NSA's requirements.

43. The IDR payment determinations for which Highmark currently seeks vacatur for Defendants' violation of the 90-day cooling off period are identified in **Exhibit B** based on Highmark's reasonable pre-suit investigation and information presently available to it.⁷ By way of example, and without limitation, the following instances illustrate Defendants' repeated and knowing violations of the 90-day cooling-off requirement:

a. On July 2, 2024, Defendants obtained an IDR payment determination for procedure code 95937 (DISP-1111499), triggering a 90-day cooling-off period. The IDR determination, which was sent to the email address medsurantarbitrationnsa@halomd.com on behalf of Bromedicon, specifically stated that Bromedicon, as the initiating party in this dispute, could not submit a subsequent Notice of IDR Initiation involving Highmark with respect to a claim for the same or similar item or service that was the subject of the dispute. It further specified that the 90-calendar day cooling-off period begins on July 2, 2024. Despite this clear notice, **just two**

⁷ Because the challenged IDR submissions and determinations involve a high volume of records and information uniquely within Defendants' possession or control, Highmark continues to review the relevant data and reserves the right to supplement, amend, or conform Exhibit B and its requested relief to the evidence developed through discovery, expert analysis, and further investigation.

days later, on July 4, 2024, Defendants initiated three more disputes for the identical procedure code: DISP-1503706, DISP-1503741, and DISP-1503794—each in knowing violation of the cooling-off period.

b. The violations for procedure code 95937 continued to cascade over the ensuing months as additional determinations within the same cooling-off period restarted the 90-day clock and provided Defendants with repeated, individualized notice of the cooling-off restriction. On September 20, 2024, Defendants obtained another determination for procedure code 95937 (DISP-992261), again expressly notifying Defendants of the 90-day prohibition and restarting the cooling-off period. **Just three days later**, on September 23, 2024, Defendants initiated three more disputes for the same code: DISP-1825159, DISP-1825365, and DISP-1825758. On March 10, 2025, yet another determination was issued (DISP-2626809), and on **that very same day**—March 10, 2025—Defendants initiated another dispute (DISP-2732696), followed by an additional dispute **just two days later** on March 12, 2025 (DISP-2748772). On March 25, 2025, another determination was issued (DISP-2685240), and **the very next day**, March 26, 2025, Defendants filed yet another dispute (DISP-2845684). On April 8, 2025, a determination was issued (DISP-2109522), and **just two days later**, on April 10, 2025, Defendants initiated two more disputes: DISP-2974479 and DISP-2977484.

c. Defendants' pattern of serial violations is further illustrated by their conduct with respect to procedure code 95941. On September 20, 2024, Defendants obtained an IDR payment determination for procedure code 95941 (DISP-1503693), triggering a 90-day cooling-off period. The IDR determination, which was sent to the email address medsurantarbitrationnsa@halomd.com on behalf of Bromedicon, specifically stated that Bromedicon, as the initiating party in this dispute, could not submit a subsequent Notice of IDR

Initiation involving Highmark with respect to a claim for the same or similar item or service that was the subject of the dispute. It further specified that the 90-calendar day cooling-off period begins on September 20, 2024. Despite this clear notice, Bromedicon, or HaloMD on behalf of and in coordination with Bromedicon, using the email address medsurantarbitrationnsa@halomd.com, initiated **just three days later**, on September 23, 2024, three additional IDR disputes for the identical procedure code: DISP-1825342, DISP-1826149, and DISP-1826545—each in knowing violation of the 90-day cooling-off period.

d. The violations for procedure code 95941 continued to cascade as additional determinations within the same cooling-off period restarted the 90-day clock and provided Defendants with repeated, individualized notice of the cooling-off restriction. These determinations included, among others: DISP-1669943 (October 8, 2024), DISP-1733906 (October 17, 2024), DISP-1826149 (October 24, 2024), DISP-1826545 (October 25, 2024), and DISP-1761711 (November 23, 2024), DISP-2053083 (December 31, 2024).

e. On January 14, 2025, Defendants obtained another determination for procedure code 95941 (DISP-2253787), again expressly notifying Defendants of the 90-day prohibition and restarting the cooling-off period. **Just one day later**, on January 15, 2025, Defendants initiated two more disputes for the same code: DISP-2419610 and DISP-2419708. On February 21, 2025, yet another determination was issued (DISP-2536968), again restarting the clock and providing express notice of the prohibition. **The very next day**, on February 22, 2025, Defendants initiated two more disputes (DISP-2626973 and DISP-2626984). On February 26, 2025, another determination was issued (DISP-2419708), and **just two days later**, on February 28, 2025, Defendants initiated three additional disputes: DISP-2670525, DISP-2671606, and DISP-2671621. On March 11, 2025, another determination was issued (DISP-2626984), and **one**

day later, on March 12, 2025, Defendants filed yet another dispute (DISP-2748620). On April 7, 2025, a determination was issued on that very dispute (DISP-2748620), and **just two days later**, on April 9, 2025, Defendants initiated another dispute (DISP-2956595).

f. Defendants engaged in the same pattern with respect to procedure code 95938. On July 31, 2024, Defendants obtained an IDR payment determination (DISP-1503780), triggering a 90-day cooling-off period through at least October 29, 2024. The IDR determination was sent to the email address medsurantarbitrationnsa@halomd.com on behalf of Bromedicon and specifically stated that Bromedicon could not submit a subsequent Notice of IDR Initiation involving Highmark for the same or similar item or service. Despite receiving this determination, Defendants initiated another IDR dispute for the identical procedure code **on the very same day**—July 31, 2024 (DISP-1606356)—demonstrating a brazen disregard for the cooling-off restriction. This pattern repeated on April 8, 2025, when Defendants obtained another determination for the same code (DISP-2107396), and **the very next day**, on April 9, 2025, initiated two more disputes (DISP-2956579 and DISP-2957086), followed by another on April 10, 2025 (DISP-2973536)—**just two days** after the determination that expressly reiterated the prohibition.

g. The same conduct occurred with procedure code 95939. On December 12, 2024, Defendants obtained an IDR payment determination (DISP-2024424), triggering a 90-day cooling-off period through at least March 12, 2025. The IDR determination was sent to the email address medsurantarbitrationnsa@halomd.com on behalf of Bromedicon and specifically stated that Bromedicon could not submit a subsequent Notice of IDR Initiation involving Highmark for the same or similar item or service. Despite this clear notice, **just one day later**, on December 13, 2024, Defendants initiated another dispute for the same code (DISP-2253796). The violations continued to cascade. On March 25, 2025, Defendants obtained another determination for

procedure code 95939 (DISP-2671618), restarting the cooling-off period and once again providing express notice of the 90-day prohibition. **The very next day**, March 26, 2025, Defendants initiated two more disputes (DISP-2847746 and DISP-2848395). On June 26, 2025, yet another determination was issued (DISP-3269945), and **the following day**, June 27, 2025, Defendants initiated another dispute (DISP-3514884), followed by two more on June 30, 2025 (DISP-3527850 and DISP-3529143)—**just four days after** the determination. As with procedure code 95941, each successive determination for procedure code 95939 restarted the cooling-off clock and provided Defendants with additional, individualized notice of the restriction, yet Defendants continued their pattern of serial violations without interruption.

h. On January 2, 2025, Defendants obtained an IDR payment determination for procedure code 95868 (DISP-2253792), triggering a 90-day cooling-off period through at least April 2, 2025. The IDR determination was sent to the email address medsurantarbitrationnsa@halomd.com on behalf of Bromedicon and specifically stated that Bromedicon, as the initiating party, could not submit a subsequent Notice of IDR Initiation involving Highmark with respect to a claim for the same or similar item or service. It further specified that the 90-calendar day cooling-off period begins on January 2, 2025. Despite this clear notice, **just one day later**, on January 3, 2025, Bromedicon, or HaloMD on behalf of and in coordination with Bromedicon, using the email address medsurantarbitrationnsa@halomd.com, initiated another dispute for the identical procedure code (DISP-2356142).

44. Defendants' pattern of initiating new IDR disputes after receiving an IDR award for the identical procedure code is not the product of inadvertence or mistake. The IDR Portal's Qualification Questions specifically inquire about prior IDR determinations and the applicable

cooling-off period. To submit these ineligible disputes, Defendants had to provide false information about prior determinations and falsely attest that the disputes were eligible for IDR.

45. Defendants knew, at the time each such dispute was initiated, that an IDR determination had been made on the same services and involving the same payor—Highmark—within the preceding 90 calendar days. Bromedicon knew because it had been a party to the prior determination, and HaloMD knew because, upon information and belief, it served as Bromedicon’s third-party biller and IDR administrator and prepared, transmitted, or caused to be transmitted both the prior and subsequent disputes.

46. As a further indication of Defendants’ knowing and intentional conduct, the sheer volume and timing of these filings demonstrate a calculated strategy to exploit the IDR system before Highmark or the IDREs can identify and object to the ineligibility of the disputes. The 90-day cooling-off period requires a health plan to cross-reference each newly initiated dispute against every prior IDR determination involving the same provider and the same procedure code, to determine whether the new dispute falls within a prior cooling-off window. Performing that analysis in real time is extraordinarily difficult—and, as a practical matter, not reasonably possible—given the volume of disputes Defendants file on top of the hundreds of disputes initiated each day by other out-of-network providers and their representatives across the country.

47. During the first half of 2025 alone, disputing parties initiated more than 1.18 million disputes nationwide, and HaloMD alone was filing an average of nearly 1,262 disputes per day. Highmark receives only a Notice of IDR Initiation—not a flag identifying a potential cooling-off violation—and must identify any eligibility deficiency and raise formal objection within three business days. Highmark performed more than reasonable diligence with respect to IDR disputes, but in real time could not perform a forensic-level, dispute-by-dispute reconciliation of thousands

of incoming IDR initiations each day against a rolling database of every prior determination, for every procedure code, for every provider, across every 90-day window.

48. Highmark has now been able to reconstruct and trace Defendants' pattern of cooling-off violations as set forth in detail in this Complaint. But the fact that these violations are identifiable in hindsight does not mean they were reasonably detectable at the speed the IDR process demands.

49. As a result, Highmark has been compelled to pay IDR awards on disputes that were ineligible for the IDR process in the first place—and to pay those awards at rates far exceeding the QPA that Congress expected would serve as the baseline in most IDR proceedings. In some instances, the awards Defendants obtained exceeded even the providers' own billed charges. Highmark has to date been stuck bearing the financial consequences of Defendants' fraud: bound by payment determinations that should never have been rendered, at prices inflated well beyond any measure of reasonable reimbursement.

50. The IDR process has been overwhelmed by a staggering volume of disputes that far exceed the government's initial estimates. Before the IDR process launched, CMS estimated that parties would initiate about **17,000 IDR disputes** each year.⁸ Providers have shattered those estimates. To say that out-of-network providers have filed more IDR cases than anticipated would be a gross understatement. In only **the first nine months** after the IDR system opened in 2022, about **190,000 disputes** were filed—*more than ten times* the number expected for the first year alone. From 2022 to June 2025, more than 3.4 million disputes were filed.⁹ And the number of

⁸ See *Requirements Related to Surprise Billing; Part II*, 86 Fed. Reg. 55,980, 56,056 (Oct. 7, 2021), available at <https://www.federalregister.gov/documents/2021/10/07/2021-21441/requirements-related-to-surprise-billing-part-ii>.

⁹ See Jack Hoadley, Kennah Watts, Katie Keith, & Ellie DeGarmo, *The No Surprises Act IDR Process: An Early Look At 2025 Data*, HEALTH AFFAIRS (Mar. 20, 2026), available at <https://www.healthaffairs.org/content/forefront/no-surprises-act-idr-process-early-look-2025-data>.

disputes is only continuing to increase: Even more recent bi-monthly updates from CMS show that nearly 1.4 million cases were filed from July 2025 through December 2025.¹⁰ This has resulted in a whopping **4.8 million total cases** through the end of 2025.¹¹

51. In the second half of 2024, disputing parties—virtually all of whom are providers—initiated **853,374 disputes, 40% more** than the first half of 2024 (610,498).¹² This figure from **six months** is more than **50 times** the volume of disputes the government originally anticipated for a **full year**. Similar to the last six months of 2024, the first half of 2025 “was characterized by an increasingly large volume of disputes submitted through the Federal IDR portal.”¹³ Disputing parties initiated **1,186,812 disputes, 39% more** than the second half of 2024 (853,374 disputes), with providers or their representatives initiated the majority of disputes (**81%**).¹⁴

52. Government reporting also shows that most disputes are initiated by a small number of providers and their representatives. The top ten initiating parties represented approximately 69% of all disputes initiated in the first six months of 2025, similar to the last six months of 2024 (71%), and the top three initiating parties accounted for about 44% of disputes.¹⁵

¹⁰ See Federal IDR bi-monthly reports, <https://www.cms.gov/nosurprises/policies-and-resources/Reports>.

¹¹ See Jack Hoadley, Kennah Watts, Katie Keith, & Ellie DeGarmo, *The No Surprises Act IDR Process: An Early Look At 2025 Data*, HEALTH AFFAIRS (Mar. 20, 2026), available at <https://www.healthaffairs.org/content/forefront/no-surprises-act-idr-process-early-look-2025-data>.

¹² *Supplemental Background on the Federal IDR Public Use Files, July 1, 2024—Dec. 31, 2024* (as of May 28, 2025), available at <https://www.cms.gov/files/document/federal-idr-supplemental-background-2024-q3-2024-q4.pdf>.

¹³ *Supplemental Background on the Federal IDR Public Use Files, January 1, 2025—June 30, 2025* (as of Jan. 21, 2026), available at <https://www.cms.gov/files/document/federal-idr-supplemental-background-2025-q1-2025-q2.pdf>.

¹⁴ *Id.* at 2.

¹⁵ *Id.*

53. HaloMD ranks as the most frequent filer of IDR disputes among the top three initiating parties. During the first six months of 2025, HaloMD initiated **230,297 IDR disputes**,¹⁶ accounting for **17%** of all disputes in the first quarter of 2025 and **22%** of all disputes in the second quarter of 2025—which by itself exceeded the government’s original estimate for total annual disputes **more than thirteenfold**. That means HaloMD was initiating an average of nearly **1,262 disputes against health plans per day**. HaloMD won slightly less often but still prevailed in **87%** and **82%** of its disputes in the first two quarters of 2025, respectively.

54. IDREs must process eligibility and payment issues within compressed timelines and often rely on the initiating party’s representations in the Notice of IDR Initiation. Defendants exploited those procedures by submitting high volumes of disputes and repeatedly attesting to eligibility even where the 90-day cooling-off period barred the dispute.

55. Government data confirms that providers prevail in the substantial majority of IDR payment determinations and that provider awards frequently exceed the QPA. In the most recent reporting period, providers prevailed in **88%** of IDR payment determinations, compared with 85% in 2024 and 81%, in 2023,¹⁷ and the median amounts awarded routinely exceeded the QPA—including the median awards of approximately **920%** and **835%** of the QPA in HaloMD-initiated disputes in the first two quarters of 2025, respectively,¹⁸ and a median award of approximately **2,862%** of the QPA for neurology procedures of the type that Bromedicon provides in the second

¹⁶ *Federal IDR Supplemental Tables for 2025 Q1* (as of Jan. 21, 2026), available at <https://www.cms.gov/files/document/federal-idr-supplemental-tables-2025-q1.xlsx>; *Federal IDR Supplemental Tables for 2025 Q2* (as of Jan. 21, 2026), available at <https://www.cms.gov/files/document/federal-idr-supplemental-tables-2025-q2.xlsx>.

¹⁷ *Supplemental Background on the Federal IDR Public Use Files, January 1, 2025—June 30, 2025* (as of Jan. 21, 2026) at 4, available at <https://www.cms.gov/files/document/federal-idr-supplemental-background-2025-q1-2025-q2.pdf>.

¹⁸ See Jack Hoadley, Kennah Watts, Katie Keith, & Ellie DeGarmo, *The No Surprises Act IDR Process: An Early Look At 2025 Data*, HEALTH AFFAIRS (Mar. 20, 2026), <https://www.healthaffairs.org/content/forefront/no-surprises-act-idr-process-early-look-2025-data>.

quarter of 2025.¹⁹ These volume and award patterns are alleged to provide context for the financial incentives that drove Defendants' misconduct and for the practical impossibility of detecting Defendants' misrepresentations and IDR ineligibility in real time.

B. Misrepresentations in IDR Submissions Concealed from Highmark

56. In addition to Defendants' knowing violation of the 90-day cooling-off period, Highmark has recently obtained IDR submission packages from IDREs and discovered, for the first time, that Defendants made blatant and material misstatements in its IDR submissions—misstatements that were concealed from Highmark by the blind nature of the IDR process and that Highmark could not have discovered or challenged during the pendency of the IDR proceedings.

57. First, in multiple IDR submissions, Defendants presented purported evidence regarding the QPA that was not specific to the disputes at issue and was materially misleading. Rather than relying on data relevant to the Highmark plans, time periods, and geographic regions at issue, Defendants submitted reimbursement data derived from different payors and materially different geographic markets—often reflecting regions with known higher reimbursement rates. This approach contravenes the statutory requirement that the QPA be based on the median of the contracted rates actually recognized by the specific plan or issuer for the same or similar item or service, furnished by providers in the same or similar specialty and within the same geographic region—not rates paid by other payors or to unrelated providers. *See* 42 U.S.C. § 300gg-111(a)(3)(E). In addition, much of the data cited by Defendants (drawn from payors other than Highmark) predated the NSA and therefore could not reliably reflect post-NSA market conditions or QPA benchmarks.

¹⁹ *See Federal IDR Supplemental Tables for 2025 Q2* (as of Jan. 21, 2026), available at <https://www.cms.gov/files/document/federal-idr-supplemental-tables-2025-q2.xlsx>.

58. Defendants used this irrelevant and outdated data to create the false impression that Highmark's QPA was artificially low and that significantly higher reimbursement rates were warranted. By presenting non-comparable data as though it were representative of the applicable market and payor, Defendants misled IDREs into crediting inflated payment offers that were not supported by the facts of the underlying disputes.

59. These same data points and purported comparators were used repeatedly across multiple IDR submissions. The repeated use of identical examples demonstrates that Defendants were not engaging in individualized, dispute-specific analysis, but instead were relying on standardized, pre-selected data designed to systematically skew IDR outcomes in their favor.

60. Second, in multiple IDR submissions, Defendants falsely represented to the IDREs that Highmark failed to participate in discussions regarding in-network reimbursement rates. In reality, Highmark engaged (and continues to engage) in communications aimed at establishing reasonable in-network reimbursement rates and negotiating contractual arrangements with Bromedicon. These misrepresentations were material because they were intended to depict Highmark as unresponsive or unwilling to negotiate in good faith, thereby skewing the IDREs' payment determinations and assessments of the parties' conduct in Defendants' favor.

61. In an effort to substantiate these misrepresentations, Defendants submitted to the IDREs a document styled as a "Request for In-Network Contract Rates" letter, which they claimed had been sent by Bromedicon (or HaloMD on its behalf) to demonstrate good-faith efforts to negotiate in-network rates. Highmark never received any such letter, because, on information and belief, Defendants never transmitted it.

62. The sham nature of the letter is backed up by multiple indicia of inauthenticity on its face, including the use of generic placeholders—such as "Health Plan," "Provider," "IONM

Practice,” and “Neurology Practice”—in place of actual party names, references to a health plan located in Texas rather than Highmark’s service area in Pennsylvania, and incorrect or non-existent contact information for Bromedicon. Moreover, the letter is substantially similar in format, structure, and language to communications that Highmark has received from other out-of-network providers or their billing agents, further suggesting that the document is a repurposed template rather than a genuine communication authored by or on behalf of Bromedicon. These defects, together with the repeated use of identical template documents across multiple disputes, confirm that the letter was not a genuine communication, but rather a generic template—used by other providers or their agents—that Defendants repurposed and submitted as though it were an authentic record of Bromedicon’s own, most recent outreach to Highmark.

Subject: Request for In-Network Contract Rates

Dear **Health Plan**,

Please accept this request on behalf of the “IONM Practice” an established and well-respected neurology practice specializing in intraoperative neuromonitoring located in state of Texas. As an out-of-network provider with **Health Plan**, “Health Plan”, our IONM Practice has been providing vital intraoperative neurology services to numerous patients who are beneficiaries of your health plan. Our practice is known for its commitment to quality patient care, a high standard of professional ethics, and advanced clinical expertise.

Intraoperative neurologists play a critical role in surgical procedures, providing real-time monitoring of a patient’s neurophysiological functions. This unique and advanced service requires a high level of training, expertise, and precision, thereby enhancing surgical outcomes and reducing potential complications. Due to these special skills and advanced nature of our work, intraoperative neurology services typically command a higher level of reimbursement.

Our practice, being dedicated to this specialized field, has invested heavily in equipment, training, and maintaining a highly qualified team, which are all reflected in the higher cost of services. Nevertheless, we are committed to providing these services because of the significant benefits they confer to patients, particularly in mitigating neurological risks during complex surgeries.

Given the significant role we play in enhancing patient safety during surgical procedures, we believe it is important to negotiate a contract with you as the health plan that accurately reflects the level of care and expertise we provide. By offering in-network services, we can ensure that our mutual patients receive the care they need at a reasonable cost, thereby increasing their access to these essential specialized services.

We are eager to discuss the possibility of transitioning to an in-network status with your health plan and negotiate a fair contract rate that takes into account the specialized nature of our services.

Please feel free to reach me directly at payor-contracting@mdms.com to arrange a suitable time for this discussion.

Thank you for considering our request. We look forward to your positive response.

Sincerely,

Neurology Practice

63. In the actual email communications between Bromedicon and Highmark—which Defendants conspicuously did not submit to the IDREs—Bromedicon used entirely different language, formatting, and substance than what appears in the sham letter. At various times, Bromedicon communicated with Highmark by email regarding reimbursement and contracting matters, but the content of those emails bears no resemblance to the polished template letter that Defendants submitted to the IDREs as purported evidence of Bromedicon’s outreach. Defendants possessed the real email communications and knew that they bore no resemblance to the sham letter, yet chose to submit the sham letter.

64. Defendants’ decision to submit a generic template letter with no apparent connection to the disputed claims—rather than the actual email communications between Bromedicon and Highmark in their possession—shows fraudulent intent. Defendants took an off-the-shelf template letter circulated among out-of-network providers and their billing agents, repurposed it as Bromedicon’s own correspondence, and submitted it to the IDREs as genuine—knowing the blind IDR process would prevent Highmark from discovering Defendants’ sham document and submitting to the IDRE the real email communications between the parties.

65. Defendants submitted the sham letter and accompanying misrepresentations directly to the IDREs in their IDR submission packages, exploiting the blind nature of the IDR process with particular deliberateness. Because Defendants had participated in actual email communications with Highmark regarding reimbursement and contracting matters, Defendants knew that Highmark possessed the real records of those communications — records that would immediately expose the sham documents as false. Defendants submitted the sham materials precisely because they knew the blind process would prevent Highmark from seeing, identifying, or rebutting them before the IDREs relied upon them.

66. In effect, Defendants exploited the procedural safeguards of the IDR process to perpetrate a fraud that could not have survived even the most basic adversarial scrutiny. Had the IDR process permitted even minimal adversarial review, the misrepresentation would have been immediately apparent: Highmark could have produced the actual email communications and demonstrated that the letter Defendants submitted was never sent and bore no resemblance to the parties' real correspondence.

67. It was only after the IDR proceedings concluded and Highmark obtained the IDR packages that these misrepresentations came to light. These misrepresentations were not discoverable by Highmark upon the exercise of due diligence prior to or during the IDR proceedings because (a) the blind process prevented Highmark from viewing Defendants' submissions; (b) there is no discovery mechanism in IDR proceedings; (c) there is no procedure for cross-examination or adversarial challenge to the other party's submissions within the IDR process; and (d) the existence of real, but entirely dissimilar, email communications between the parties gave Highmark no basis to suspect that Defendants would manufacture fictitious documents purporting to reflect different communications that never occurred.

68. The IDR payment determinations for which Highmark currently seeks vacatur for Defendants' misrepresentations in IDR submissions, which were concealed from Highmark, are identified in **Exhibit C** based on Highmark's reasonable pre-suit investigation and information presently available to it.²⁰ The following are exemplary instances in which Defendants made

²⁰ Given that every IDR submission package submitted by Defendants that Highmark has obtained thus far from the IDREs contained the same sham document and misleading QPA comparator information, Highmark believes discovery will show that most, if not all, IDRs initiated by Defendants contained these same misrepresentations, and therefore expects the number reflected in Exhibit C to increase. Accordingly, Highmark reserves the right to supplement, amend, or conform Exhibit C and its requested relief to the evidence developed through discovery, expert analysis, and further investigation.

material misrepresentations in IDR submissions that were concealed from Highmark during the IDR process and that were made to improperly influence the IDREs in Defendants' favor:

a. **Sham “Request for In-Network Contract Rates” Letter and False Negotiation Narrative:** In the IDR proceedings captioned DISP-1851702 and DISP-3528869, Defendants' IDR submission packages included a document styled as a “Request for In-Network Contract Rates” letter, attached as “Exhibit 5,” which Defendants represented had been sent by Bromedicon to Highmark as evidence of Bromedicon's good-faith efforts to negotiate in-network rates. Defendants also represented to the IDRE that Bromedicon had “extended a formal invitation to [Highmark] to enter into negotiations with the aim of establishing in-network rates and contractual agreements,” but that Highmark had “not reciprocated [Bromedicon]'s good faith efforts.” Defendants further directed the IDRE to “review [Bromedicon]'s written request for in-network reimbursement rates.” These representations were false. The letter attached as Exhibit 5 was never received by Highmark. The document is a repurposed template—substantially similar in format, structure, and language to template communications Highmark has received from other out-of-network providers and/or their billing agents—and bears no resemblance to the actual email communications between Bromedicon and Highmark. The IDRE selected Defendants' offers, substantially exceeding the QPA, as the prevailing offers and found that **“the initiating party's evidence regarding the provider's good faith contract negotiations and the provider's extensive experience was the most persuasive.”** These findings were based directly on the sham letter and false narrative that Defendants submitted. Highmark did not and could not have known of the sham document or the false representation during the IDR process because the blind submission procedure prevented Highmark from viewing Defendants' submission packages.

b. In the IDR proceedings captioned DISP-2024426, DISP-3026241, and DISP-3060503, Defendants submitted the same sham “Request for In-Network Contract Rates” letter as “Exhibit 5” and falsely represented that Bromedicon had sought to negotiate in-network rates and that Highmark had not reciprocated. In choosing Defendants’ inflated offers as the appropriate value for the services, the IDRE found that **“the initiating party’s evidence regarding the provider’s good faith efforts was the most persuasive.”** And in DISP-3060503, the IDRE also found the sham letter and Highmark’s supposed failure to reciprocate **“compelling** in substantiating that [Bromedicon]’s offer best reflects the appropriate payment amount for this claim.”

c. **Misleading QPA Data from Other Health Plans:** In the IDR proceeding captioned DISP-1851702, Defendants’ IDR submission package also cited data and reimbursement information from other health plans—*not Highmark*—in purported support of the QPA. Defendants submitted explanation of benefit forms derived from other health plans and different geographic regions, including Texas and Ohio, often reflecting markets with materially higher reimbursement rates that bear no resemblance to the geographic area in which the services at issue were rendered. Some of the data also predated the NSA’s effective date and therefore could not reliably reflect post-NSA market conditions or QPA benchmarks.

d. Defendants presented this non-comparable information to the IDRE as though it were relevant to Highmark’s QPA or otherwise probative of the appropriate out-of-network rate for services billed to Highmark’s plans in the applicable geographic area and time period. This information was misleading and irrelevant. The QPA is a plan-specific calculation based on Highmark’s own median contracted rates for the same or similar services in the same geographic region during the applicable time period. Data from different payors, different

geographic markets, and different time periods has no bearing on Highmark's QPA. By submitting reimbursement data from unrelated payors in non-comparable geographic markets and outdated time periods, Defendants sought to create the false impression that Highmark's QPA was artificially low and that a significantly higher payment was warranted. Highmark did not and could not have known of this misleading submission during the IDR process because the blind submission procedure prevented Highmark from viewing Defendants' submission package.

e. Defendants submitted similar misleading and irrelevant reimbursement data from other payors – not Highmark – in support of their payment offers for many other disputes, including, among others: DISP-2024426 and DISP-3026241 (same data from Anthem and Blue Cross Blue Shield of Texas for services rendered provided by Texas providers between 2020 and 2022); DISP-3026243 (data from Blue Cross Blue Shield of Texas, Cigna, and Meritain Health for services rendered by Texas providers in 2022); and DISP-3721525 (Anthem for services rendered in 2019).

69. Each of these misrepresentations was material because the NSA requires the IDRE to consider the QPA and additional circumstances in making its payment determination, and misrepresentations about the QPA and the parties' conduct during negotiations directly affected the IDRE's evaluation of the parties' competing offers.

C. HaloMD's Role and Incentives

70. The relationship between Bromedicon and HaloMD was not that of independent entities engaged in ordinary vendor services. Rather, upon information and belief, Bromedicon and HaloMD acted in coordination and concert to generate, submit, and prosecute IDR disputes arising from Bromedicon's out-of-network claims.

71. HaloMD markets itself as operating with an “exclusive focus on Independent Dispute Resolution (IDR)” and holds itself out as an expert in navigating the NSA’s dispute-resolution framework.

72. HaloMD’s business model is built around maximizing reimbursement through the IDR process. HaloMD advertises that it achieves “industry leading results,” including awards that are multiples higher than the QPA, and reports securing billions of dollars in IDR determinations annually.

73. HaloMD is financially incentivized to increase both the size and volume of IDR awards. Upon information and belief, HaloMD charges its provider clients a contingency-based fee tied to the amounts recovered, aligning its financial interests with maximizing reimbursement rather than ensuring compliance with statutory requirements.

74. Consistent with this incentive structure, HaloMD operates “at scale,” using centralized and automated systems to initiate and prosecute IDR disputes in high volumes on behalf of affiliated providers. HaloMD touts its “proprietary platform” as one founded with “advanced technology” and “AI-driven” infrastructure. HaloMD also represents that it “instantly assesses each case for eligibility under The No Surprises Act and relevant state regulations.” HaloMD further represents that it “gathers and organizes the necessary documentation [from the provider], [and] prepar[es] a compelling case that highlights the provider’s position, ensuring nothing is overlooked[.]” Providers, like Bromedicon, submit services for dispute in the IDR process through HaloMD’s portal.

75. In a short period of time since its founding in 2022, HaloMD has become one of the largest participants in—and abusers of—the federal IDR process. The combination of contingency-based compensation, high-volume processing, and demonstrated disregard for

statutory requirements creates powerful incentives for HaloMD to submit as many IDR disputes as possible and to pursue the highest possible reimbursement amounts, including through disputes that do not satisfy the NSA's eligibility criteria.

76. As a result, HaloMD's financial interests are directly aligned with pursuing aggressive and improper IDR strategies on behalf of its provider clients—including Bromedicon—regardless of whether the underlying disputes are eligible, timely, or otherwise proper.

VII. Defendants' Conduct Has Caused Substantial Harm to Highmark

77. As a direct and proximate result of Defendants' fraudulent conduct, Highmark has suffered injuries, including excessive payments procured through false attestations of eligibility and material misrepresentations in IDR submissions.

78. Highmark has also incurred substantial administrative and IDRE fees in connection with Defendants' ineligible disputes. Both parties to an IDR proceeding must pay a non-refundable administrative fee when a dispute is initiated. This fee is not recoverable even when the dispute is determined to be ineligible for IDR. Both parties must also pay an IDRE fee before the IDRE makes the payment determination.

79. Moreover, Highmark has been forced to divert significant internal resources and costs to process and respond to Defendants' ineligible and fraudulently procured IDR disputes, resources that would otherwise be devoted to serving Highmark's members and plan participants.

80. The financial harm caused by Defendants' fraudulent practices is ongoing and threatens the affordability and sustainability of health benefits for Highmark's members and ASO customers. This includes self-funded groups such as state and local governmental entities, public school districts, and labor unions—budget-constrained entities that rely on Highmark to manage costs, and whose exposure to inflated claims directly damages Highmark's business relationships

and competitive position. Excessive IDR awards drive up health care costs, which ultimately may result in higher premiums for consumers. The costs to employers and health plan members are inextricably linked to the reimbursement rates that health plans negotiate with each health care provider in their provider network. If left unchecked, Defendants' conduct will continue to deplete funds set aside for covering healthcare for citizens of Pennsylvania and nationwide, incentivize copy-cat behavior by other out-of-network providers, and make it more difficult for health plans like Highmark to build provider networks that help control the cost and quality of healthcare. Defendants' conduct also places providers who do the right thing—either by contracting with health plans and honoring the reimbursement rates they agreed to or by charging fair, market rates for out-of-network services—at a substantial competitive disadvantage.

COUNT I

VACATUR OF IDR PAYMENT DETERMINATIONS PROCURED BY FRAUD, UNDUE MEANS, AND MISREPRESENTATIONS OF FACT, AND ISSUED IN EXCESS OF IDRE AUTHORITY (42 U.S.C. § 300gg-111(c)(5)(E); 9 U.S.C. § 10(a)(1), (4))

81. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

82. The NSA provides that a determination of a certified IDR entity under subparagraph (A) “(I) shall be binding upon the parties involved, in the absence of a fraudulent claim or evidence of misrepresentation of facts presented to the IDR entity involved regarding such claim,” and “(II) shall not be subject to judicial review except in a case described in any of paragraphs (1) through (4) of section 10(a) of title 9.” 42 U.S.C. § 300gg-111(c)(5)(E)(i). Section 10(a) of the FAA permits vacatur where, among other things, an award was “procured by corruption, fraud, or undue means,” 9 U.S.C. § 10(a)(1), or where “the arbitrators exceeded their powers, or so imperfectly executed them that a mutual, final, and definite award upon the subject matter submitted was not made,” *id.* § 10(a)(4). Highmark invokes both the NSA’s exception to

binding effect for fraudulent claims and misrepresentations of fact and the FAA vacatur grounds incorporated by 42 U.S.C. § 300gg-111(c)(5)(E)(i)(II).

83. Count I seeks vacatur of the IDR payment determinations identified in Exhibit A and the representative examples alleged above on three related grounds. First, the challenged determinations were issued in the absence of binding effect under the NSA because Defendants presented fraudulent claims or evidence of misrepresentations of facts to the IDREs. Second, the determinations were procured by fraud or undue means within the meaning of § 10(a)(1), including through sham negotiation materials, false negotiation narratives, and misleading reimbursement comparators concealed from Highmark by the blind IDR process. Third, the IDREs exceeded their powers within the meaning of § 10(a)(4) by issuing payment determinations on disputes that were not qualified IDR items or services.

84. Highmark did not know, and could not reasonably have known, of the concealed misrepresentations before or during the IDR proceedings. Highmark first uncovered the misleading submission materials only after obtaining IDR submission packages following the close of the proceedings, and it acted diligently thereafter to investigate the scope of the misconduct.

85. For the excess-of-authority ground, the challenged determinations identified in Exhibit A and the representative examples alleged above involving disputes submitted during an unexpired 90-day cooling-off period should be vacated under § 10(a)(4). The NSA authorizes IDR payment determinations only for qualified IDR items or services, and disputes barred by the 90-day cooling-off period are not qualified IDR items or services; by issuing payment determinations on those disputes, the IDREs exceeded their powers. Highmark pleads that § 10(a)(4) ground without waiving the alternative argument that threshold eligibility determinations on non-

qualified, inarbitrable disputes fall outside the NSA's judicial review provision and therefore do not preclude the alternative tort, statutory, declaratory, and equitable claims pleaded below.

86. Under Count I, Highmark seeks an order vacating each IDR payment determination identified in Exhibit A and the representative examples alleged above, together with the amounts Highmark paid pursuant to those determinations and the associated administrative and IDRE fees.

COUNT II **FRAUD AND INTENTIONAL MISREPRESENTATION**

87. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

88. Highmark pleads this Count and the other tort, statutory, and equitable Counts that follow, in addition to, and in the alternative to, Count I. These Counts are pleaded in addition to Count I because Defendants' misconduct caused independent injuries, including but not limited to administrative and IDRE fees Highmark was forced to incur, harm caused by Defendants' submission of misleading evidence to IDREs, and the diversion of Highmark's personnel and resources to detect, investigate, and respond to Defendants' conduct. These Counts are pleaded in the alternative to Count I because, if the Court concludes that some or all of the challenged disputes were categorically ineligible for the NSA IDR process, were inarbitrable from the outset, or otherwise were not governed by the NSA's judicial-review provision, then the challenged determinations are not binding NSA IDR determinations, the NSA does not bar these Counts, and Highmark is entitled to pursue full tort, statutory, restitutionary, and equitable relief for Defendants' misconduct.

89. As set forth above, Defendants knowingly and intentionally made false representations of material fact to Highmark, the IDREs, and the federal Departments in

connection with their initiation of and participation in the IDR process. These false representations include, but are not limited to:

- a. Falsely attesting that items and services submitted to the IDR process were “qualified item(s) and/or service(s) within the scope of the Federal IDR process” when Defendants knew that the items and services were ineligible, including due to the NSA’s 90-day cooling-off period;
- b. Providing false and misleading information on the federal IDR Portal, including inaccurate responses to the Qualification Questions regarding prior IDR determinations, in order to bypass safeguards designed to prevent the submission of ineligible disputes;
- c. Submitting reimbursement data and purported comparators derived from other health plans—not Highmark—and from non-comparable geographic regions and time periods, including pre-NSA data, in purported support of the QPA and payment offers, thereby misleading IDREs as to the appropriate basis for the payment determination; and
- d. Falsely representing to IDREs that Highmark failed to engage in dialogue regarding in-network reimbursement rates.

90. Defendants made each of these representations with knowledge of their falsity. With respect to the 90-day cooling-off period violations, Bromedicon was a party to the prior IDR determinations that rendered the subsequent disputes ineligible, and HaloMD, acting on behalf of and in concert with Bromedicon, prepared, transmitted, or caused to be transmitted the subsequent disputes. With respect to the misrepresentations in IDR submissions, Defendants knew or recklessly disregarded that the reimbursement data cited was from other providers and other health plans, and that Highmark had in fact engaged in good faith discussions aimed at establishing reasonable in-network reimbursement rates and contractual agreements with Bromedicon.

91. Defendants made these false representations with the intent that Highmark, the IDREs, and the Departments rely upon them, for the purpose of obtaining money from Highmark through IDR payment determinations that Defendants knew were based on ineligible disputes and materially misleading submissions. To the extent Defendants' misrepresentations were made directly to the IDREs rather than to Highmark, Defendants specifically intended that Highmark rely upon those misrepresentations. Defendants knew that Highmark was the payor that would be bound by and compelled to pay any IDR payment determination procured through their false submissions. Defendants further knew that the blind nature of the IDR process would prevent Highmark from discovering or challenging their misstatements. Highmark was thus the foreseeable and specifically intended victim of Defendants' misrepresentations to the IDREs.

92. Highmark reasonably, foreseeably, and justifiably relied on Defendants' false representations. With respect to the false eligibility attestations, once Defendants initiated the IDR process, Highmark was compelled to participate and respond within the NSA's compressed timelines. In many instances, the sheer volume of Defendants' ineligible filings—layered on top of the hundreds of IDR disputes initiated daily by other out-of-network providers—made it practically impossible for Highmark to identify every cooling-off violation in the three business days permitted for raising eligibility objections. Tracking the 90-day cooling-off period requires cross-referencing each new dispute against every prior determination for the same procedure code, same provider, and same payor across a rolling 90-day window—a forensic-level undertaking that no health plan could reasonably be expected to perform in real time at the scale and speed the IDR process demands. Highmark necessarily relied on Defendants' portal attestations that each dispute satisfied the NSA's eligibility requirements.

93. Only with the benefit of time and forensic analysis has Highmark been able to reconstruct the full scope of Defendants' cooling-off violations. As a consequence, Highmark has been compelled to pay IDR awards on disputes that were ineligible for the IDR process in the first instance—at rates far exceeding the QPA and, in some cases, exceeding even the providers' own billed charges. With respect to the misrepresentations in IDR submissions, Highmark could not have discovered these misrepresentations during the IDR process because the blind submission process precluded Highmark from viewing Defendants' submission packages. Highmark's reliance was therefore justified because it had no opportunity to challenge or rebut these concealed misstatements.

94. As a direct and proximate result of Defendants' fraud, Highmark has suffered substantial damages, including, but not limited to: (a) payments on IDR payment determinations that were procured through ineligible disputes and material misrepresentations; (b) non-refundable administrative and IDRE fees associated with ineligible IDR disputes; and (c) expenditure of internal resources to process and respond to Defendants' fraudulent submissions.

95. Defendants' fraud was deliberate, systematic, and willful, warranting an award of punitive damages.

COUNT III
NEGLIGENT MISREPRESENTATION

96. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

97. Highmark pleads this Count in addition to, and in the alternative to, Count I, and on the same bases set forth in paragraph 87 above.

98. In submitting false attestations of eligibility and making material misrepresentations in its IDR submissions, Defendants misrepresented material facts to Highmark,

the IDREs, and the Departments regarding the eligibility and merits of the disputes it submitted to the IDR process.

99. Based on the plain text of the NSA and its implementing regulations, the information available to Defendants through the IDR Portal's Qualification Questions, Defendants' own records of prior IDR determinations, and Highmark's communications during open negotiations, Defendants had no reasonable grounds on which to believe or represent that the disputes were eligible for IDR or that the factual representations in the submissions were accurate.

100. Defendants made these misrepresentations in the course of their business and in a transaction in which they had a pecuniary interest, intending that Highmark, the IDREs, and the Departments rely upon them.

101. Highmark reasonably, foreseeably, and justifiably relied on Defendants' misrepresentations for the reasons set forth above, including that the blind nature of the IDR process precluded Highmark from discovering the misstatements in Defendants' submissions until after the proceedings concluded.

102. As a direct and proximate result of Defendants' negligent misrepresentations, Highmark has suffered substantial damages as set forth above.

COUNT IV
CIVIL CONSPIRACY

103. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

104. Highmark pleads this Count in addition to, and in the alternative to, Count I, and on the same bases set forth in paragraph 87 above.

105. Defendants knowingly agreed, combined, and acted in concert to carry out the fraudulent scheme described herein, including in connection with engaging in open negotiations,

initiating ineligible IDR disputes, preparing and submitting materially false IDR submission packages, and collecting the resulting proceeds.

106. This conspiracy is further supported by HaloMD's role as Bromedicon's third-party biller and IDR representative and by the broader affiliations and familial ties between HaloMD and MPOWERHealth, including overlapping leadership, shared business infrastructure, and the marriage of HaloMD's founder and president, Alla LaRoque, to MPOWERHealth's founder and chief executive officer, Scott LaRoque. Upon information and belief, Bromedicon is affiliated with, owned by, controlled by, or operating in concert with MPOWERHealth. Each participant in this conspiracy shared the common objective of defrauding Highmark by exploiting the IDR process through false eligibility attestations and materially misleading IDR submissions, and each committed overt acts in furtherance of the conspiracy, including the submission of false attestations, the preparation and filing of misleading IDR submission packages, the pursuit of open negotiations based on false premises, and the collection of improper IDR awards.

107. As a direct and proximate result of this conspiracy, Highmark has suffered substantial damages as set forth above.

COUNT V **UNJUST ENRICHMENT**

108. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

109. Highmark pleads this Count in addition to, and in the alternative to, Count I, and on the same bases set forth in paragraph 87 above.

110. Defendants have been unjustly enriched by receiving IDR payment determinations and associated payments from Highmark for disputes that were ineligible for the IDR process under the 90-day cooling-off period and that were procured through material misrepresentations

in Defendants' IDR submissions. Bromedicon was enriched by the resulting awards and payments, and HaloMD was enriched by commissions, fees, or other compensation tied to those awards.

111. Highmark conferred a benefit upon Defendants by making payments in compliance with IDR determinations that were the product of Defendants' fraud and misrepresentation. Defendants appreciated and knowingly accepted such benefit.

112. Under the circumstances, it would be inequitable and unjust for Defendants to retain the payments and related compensation obtained through their fraudulent conduct.

113. Highmark is entitled to restitution of all amounts improperly obtained by Defendants through the fraudulent conduct described herein.

114.

COUNT VI
DECLARATORY AND INJUNCTIVE RELIEF
UNDER 28 U.S.C. §§ 2201–2202 AND ANCILLARY EQUITABLE PRINCIPLES

115. Highmark incorporates by reference all preceding paragraphs as though fully set forth herein.

116. Highmark pleads this Count in addition to, and in the alternative to, Count I. It is pleaded in addition to Count I to the extent it provides declaratory and ancillary equitable relief that is not duplicative of the vacatur sought in Count I. It is pleaded in the alternative to Count I because, if the Court determines that some or all of the challenged disputes were categorically ineligible for the NSA IDR process, were inarbitrable from the outset, or otherwise were not governed by the NSA's judicial-review provision, then the challenged determinations identified in Exhibit A are not binding NSA IDR determinations and Defendants may not enforce, collect, or retain payment based on them.

117. An actual and justiciable controversy exists between Highmark and Defendants concerning whether Defendants may enforce or retain payments or other amounts obtained through the challenged IDR determinations identified in Exhibit A, where those determinations were procured through fraudulent claims, misrepresentations of fact, fraud, undue means, and/or were issued in disputes that were not validly subject to the NSA IDR process.

118. The Declaratory Judgment Act authorizes declaratory relief for controversies otherwise within the Court's subject-matter jurisdiction.

119. In the alternative to vacatur under Count I, Highmark seeks a declaration that the challenged determinations identified in Exhibit A are not binding, are not payable, and may not be enforced against Highmark to the extent the Court determines that those disputes were not validly subject to the NSA IDR process or that the NSA's judicial-review provision does not govern those eligibility or inarbitrability determinations.

120. Highmark further seeks targeted injunctive relief prohibiting Defendants from enforcing, collecting, retaining, or attempting to collect amounts awarded in the challenged determinations identified in Exhibit A, and from initiating or pursuing IDR proceedings against Highmark for claims that fall within the same objectively verifiable ineligibility categories identified in Exhibit A, including claims barred by the NSA's 90-day cooling-off period.

121. Highmark does not seek through this Count a generalized injunction requiring Defendants to comply with the NSA, nor does it seek an advisory declaration governing unidentified future IDR proceedings. The relief sought in this Count is limited to the challenged determinations identified in Exhibit A and objectively verifiable categories of ineligible claims arising from the same course of conduct.

PRAYER FOR RELIEF

WHEREFORE, Highmark respectfully requests that this Court enter judgment against Defendants and award Highmark the following relief:

a. An order vacating, pursuant to 42 U.S.C. § 300gg-111(c)(5)(E) and 9 U.S.C. § 10(a)(1) and (4), each IDR payment determination identified in Exhibit A and the representative examples alleged above, together with all amounts paid pursuant to those determinations and the associated administrative and IDRE fees;

b. In addition to, and in the alternative to, the vacatur relief requested above, and to the extent not duplicative of that relief, compensatory damages in an amount to be determined at trial, including all improper IDR payments, administrative fees, IDRE fees, fabricated-evidence damages, and other costs attributable to Defendants' fraudulent conduct;

c. Punitive damages in an amount sufficient to deter Defendants and others from engaging in similar fraudulent conduct;

d. Restitution and disgorgement of all amounts improperly obtained by Defendants through the fraudulent conduct described herein;

e. A declaratory judgment and injunctive relief as set forth in Count VI;

f. Pre-judgment and post-judgment interest; and

g. Such other and further relief as this Court deems just and proper.

JURY TRIAL DEMANDED

Highmark hereby demands a trial by jury on all claims and issues so triable.

Dated: June 1, 2026

Respectfully submitted,

REED SMITH LLP

By: William J. Sheridan
William J. Sheridan
Reed Smith Centre
225 Fifth Avenue
Pittsburgh, PA 15222
Telephone: (412) 288-7282
Facsimile: (412) 288-3063
wsheridan@reedsmith.com

Mark E. Bini (*pro hac vice forthcoming*)
Kaela Dahan (*pro hac vice forthcoming*)
599 Lexington Avenue
New York, NY 10022
Telephone: (212) 521-5400
Facsimile: (212) 521-5450
mbini@reedsmith.com
kdahan@reedsmith.com

Anthony R. Todd (*pro hac vice forthcoming*)
10 South Wacker Drive
Chicago, IL 60606
Telephone: (312) 207-1000
Facsimile: (312) 207-6400
atodd@reedsmith.com

Counsel for Plaintiff Highmark Inc.

EXHIBIT A

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2419658	22844522770	51785	2/10/2025	\$2,497.91	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465736	22647903058	51785	2/18/2025	\$2,497.91	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1851703	22538622076	92653	11/23/2024	\$1,098.13	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1824699	22417111938	92653	12/4/2024	\$1,208.90	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182598	22842459316	92653	1/10/2025	\$1,098.13	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412180	22847113443	92653	2/26/2025	\$1,098.13	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732697	22348592485	92653	4/1/2025	\$1,098.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3837523	22077531117	92653	9/12/2025	\$637.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3836626	22258010917	95717	9/24/2025	\$70.27	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3879208	22361306513	95717	11/17/2025	\$3,450.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3306153	22152860320	95720	6/27/2025	\$6,221.22	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4054504	22462325784	95720	10/8/2025	\$26,653.32	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1763006	22836533011	95813	10/27/2024	\$6,221.22	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503715	22233439772	95861	9/25/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1670784	22052975163	95861	10/15/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1734808	22336463461	95861	10/16/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1763008	22137237027	95861	10/27/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1843538	22055176348	95861	11/19/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491889	22414467926	95861	11/22/2024	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162935	22643758561	95861	1/15/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356143	22646186697	95861	1/23/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317354	22844586126	95861	2/3/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411997	22846296920	95861	2/5/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324108	22645904596	95861	2/6/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412174	22747047938	95861	2/6/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465728	22547350965	95861	2/14/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465735	22647903058	95861	2/14/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356134	22646295587	95861	2/25/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608195	22247923915	95861	3/6/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626808	22068564348	95861	3/7/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627480	22149163232	95861	3/10/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670526	22650130924	95861	3/24/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2977488	22552229253	95861	5/28/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216911	22755204307	95861	6/23/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3218276	22555093534	95861	6/23/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278353	22555916421	95861	6/26/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3269943	22455209987	95861	6/27/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3456257	22757285248	95861	7/28/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3459250	22557189096	95861	8/7/2025	\$7,769.59	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-4152569	22763195633	95861	10/16/2025	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2253792	22836855749	95868	1/2/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152719	22843530575	95868	1/16/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356142	22646186697	95868	1/23/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670521	22650130924	95868	3/17/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3001962	22072837086	95868	5/17/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001941	22553455043	95868	5/23/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091888	22353884451	95868	5/29/2025	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3529605	22658314815	95868	9/3/2025	\$5,100.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3722110	22559775440	95868	9/5/2025	\$3,619.33	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4461177	22365586186	95868	11/26/2025	\$5,100.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-1898975	22840424174	95870	11/10/2024	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1816460	22736130233	95870	11/23/2024	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994563	22141311388	95870	12/6/2024	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898396	22238859813	95870	12/20/2024	\$9,122.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2025423	22241247150	95870	12/24/2024	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2253790	22836855749	95870	12/31/2024	\$4,561.17	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375500	22846164385	95870	1/23/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412163	22647134173	95870	2/6/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419711	22847256641	95870	2/26/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607918	22248580476	95870	3/7/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671614	22249869117	95870	3/28/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2758893	22550706698	95870	4/8/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1898395	20259394337	95870	4/21/2025	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237429	22644607831	95870	4/21/2025	\$4,561.17	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845691	22350062937	95870	4/29/2025	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3030102	22653572517	95870	6/21/2025	\$9,122.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3663252	22078119415	95870	9/5/2025	\$5,706.28	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3720706	22559775440	95870	9/5/2025	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3878874	22761527960	95870	10/3/2025	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2536969	22148279392	95885	2/27/2025	\$13,055.18	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2890176	22251956203	95885	6/11/2025	\$13,055.18	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182606	22844079297	95886	1/10/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237927	22443823892	95886	1/30/2025	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237939	22844586127	95886	1/30/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419649	22844522770	95886	2/12/2025	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419723	22846636199	95886	2/12/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419628	22444489677	95886	2/18/2025	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608132	22348592484	95886	3/13/2025	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685243	22850114802	95886	3/23/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670529	22650002761	95886	3/24/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608249	22548727476	95886	3/25/2025	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685232	22069858988	95886	3/25/2025	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2977227	22071423284	95886	5/28/2025	\$6,678.94	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3515034	22356144464	95886	8/1/2025	\$566.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4203260	22080688063	95886	10/24/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4022121	22361630511	95886	11/12/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4052655	22562560966	95886	11/21/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4162031	22563127650	95886	11/25/2025	\$566.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851101	22538622076	95887	11/23/2024	\$7,606.54	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2685248	22064731364	95887	3/14/2025	\$3,339.47	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182609	22844079297	95907	1/14/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237941	22844586127	95907	1/30/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419654	22844522770	95907	2/12/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419724	22846636199	95907	2/12/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685234	22069858988	95907	3/23/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670533	22650002761	95907	3/25/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685246	22064731364	95907	3/25/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685242	22850114802	95907	3/26/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2957079	22035849365	95907	5/27/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216915	22651454339	95907	6/27/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3514754	22356144464	95907	8/4/2025	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4164166	22563127650	95907	10/25/2025	\$6,120.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237929	22443823892	95908	1/30/2025	\$2,293.20	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536973	22148279392	95908	2/24/2025	\$2,293.20	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2890177	22251956203	95908	6/27/2025	\$3,870.92	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2608247	22348592484	95909	3/21/2025	\$5,201.89	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2969059	22071423284	95909	5/16/2025	\$2,231.86	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3457200	22657544591	95909	7/28/2025	\$849.15	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343198	22129855904	95937	6/19/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343213	22429243808	95937	7/28/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503794	22833577311	95937	8/5/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1371433	NA780262405025988 00	95937	8/11/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1406316	22131533373	95937	8/15/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503706	22233439772	95937	9/19/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503741	22833667576	95937	9/20/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1612642	22235231286	95937	9/20/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1673307	22052975163	95937	10/2/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1732928	22335859346	95937	10/15/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1732926	22336463461	95937	10/16/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760077	22836533011	95937	10/21/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1762954	22137237027	95937	10/22/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852799	22538622076	95937	10/31/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1899485	22840424174	95937	11/5/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825365	22417111938	95937	11/18/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825159	22738652771	95937	11/19/2024	\$6,957.73	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825758	22336104061	95937	11/20/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1844325	22055176348	95937	11/20/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491879	22414467926	95937	11/22/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1755759	22436779390	95937	11/23/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852254	22539693367	95937	11/23/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898774	20259394337	95937	11/24/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994052	22141311388	95937	12/9/2024	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024421	22341617799	95937	12/27/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2253791	22836855749	95937	12/31/2024	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2053089	22742624416	95937	1/2/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182604	22844079297	95937	1/10/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162932	22643758561	95937	1/15/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182599	22842459316	95937	1/15/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152720	22843530575	95937	1/16/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355868	22646295587	95937	1/22/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375319	22846164385	95937	1/23/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237925	22443823892	95937	1/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237940	22844586127	95937	1/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237949	22342490541	95937	1/30/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317353	22844586126	95937	2/3/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324105	22645904596	95937	2/6/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411996	22846296920	95937	2/6/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412181	22847113443	95937	2/6/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412173	22747047938	95937	2/7/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419722	22846636199	95937	2/12/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2419728	22844522770	95937	2/12/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465723	22547350965	95937	2/13/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412162	22647134173	95937	2/14/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465733	22647903058	95937	2/14/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536967	22148279392	95937	2/21/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419629	22444489677	95937	2/25/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419712	22847256641	95937	2/26/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2529618	22246304477	95937	2/26/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607917	22248580476	95937	3/6/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608246	22348592484	95937	3/7/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356138	22646186697	95937	3/10/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626809	22149163232	95937	3/10/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626807	22068564348	95937	3/17/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608135	22247923915	95937	3/19/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670520	22650130924	95937	3/20/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607923	22548727476	95937	3/21/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670530	22650002761	95937	3/21/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671613	22249869117	95937	3/24/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685089	22069858988	95937	3/25/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685240	22850114802	95937	3/25/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748772	22550706698	95937	4/3/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732696	22348592485	95937	4/7/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2109522	22443235302	95937	4/8/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237426	22644607831	95937	4/21/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845684	22346901967	95937	4/29/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890178	22251956203	95937	4/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956597	22553455042	95937	5/13/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977226	22071423284	95937	5/16/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001956	22072837086	95937	5/17/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3029706	22653572517	95937	5/17/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2957076	22035849365	95937	5/23/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2974479	22749389876	95937	5/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091879	22353884451	95937	5/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216914	22651454339	95937	6/22/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3277945	22075139592	95937	6/26/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3316162	22756486572	95937	6/27/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3218275	22555093534	95937	6/30/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278355	22555916421	95937	7/23/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3455689	22657544591	95937	7/28/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3458749	22557189096	95937	7/28/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977484	22552229253	95937	7/29/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3529144	22658314815	95937	8/1/2025	\$619.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3514465	22356144464	95937	8/5/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3456768	22757285248	95937	8/7/2025	\$3,112.70	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3531463	22257504137	95937	9/5/2025	\$4,484.49	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3664015	22078119415	95937	9/5/2025	\$557.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721960	22559775440	95937	9/24/2025	\$619.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3924438	22461748815	95937	10/3/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4020667	22361630511	95937	10/3/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4202600	22080688063	95937	11/6/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3841346	22077531117	95937	11/14/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3879225	22761527960	95937	11/25/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1037207	22221528553	95938	5/27/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	iMPROVe Health
DISP-1338654	22042317633	95938	6/19/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343160	22529010348	95938	6/24/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343189	22129855904	95938	6/25/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1111501	22122421292	95938	7/10/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1303798	22626305199	95938	7/13/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-992251	22416670314	95938	7/17/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1406308	22131533373	95938	7/25/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343206	22429243808	95938	7/28/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503780	22833577311	95938	7/31/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	Federal Hearings and Appeals Services, Inc.
DISP-966291	22817141024	95938	7/31/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-992306	22719286509	95938	8/5/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	MCMC Services, LLC
DISP-1491870	22414467926	95938	8/21/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1338866	22129855905	95938	8/26/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1371429	NA780262405025988 00	95938	8/27/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1053526	22820639402	95938	8/29/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1606356	22333030702	95938	9/14/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503733	22833667576	95938	9/18/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503702	22233439772	95938	9/19/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-914536	22714160939	95938	10/15/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733315	22335859346	95938	10/16/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733620	22336463461	95938	10/16/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760164	22137237027	95938	10/22/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1761756	22836533011	95938	10/25/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1844027	22055176348	95938	10/25/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852059	22539693367	95938	10/28/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1854105	22538622076	95938	10/31/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898790	22840424174	95938	11/10/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1816626	22736130233	95938	11/14/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826540	22417111938	95938	11/17/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1758059	22436779390	95938	11/20/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994442	22141311388	95938	12/5/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2253789	22836855749	95938	12/30/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2025370	22241247150	95938	12/31/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053087	22742624416	95938	12/31/2024	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182603	22844079297	95938	1/10/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162927	22643758561	95938	1/15/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152717	22843530575	95938	1/16/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355866	22646295587	95938	1/22/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1898976	20259394337	95938	1/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237438	22443823892	95938	1/30/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237938	22844586127	95938	1/30/2025	\$10,909.93	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237946	22342490541	95938	1/30/2025	\$10,909.93	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317351	22844586126	95938	2/3/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2323768	22645904596	95938	2/6/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412000	22846296920	95938	2/6/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412161	22647134173	95938	2/6/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412172	22747047938	95938	2/6/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2420764	22444489677	95938	2/10/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375315	22846164385	95938	2/12/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419719	22846636199	95938	2/12/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419729	22844522770	95938	2/12/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465726	22547350965	95938	2/13/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465734	22647903058	95938	2/14/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412178	22847113443	95938	2/24/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536966	22148279392	95938	2/24/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419709	22847256641	95938	2/26/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608161	22348592484	95938	3/6/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356137	22646186697	95938	3/10/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627406	22149343815	95938	3/12/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607921	22247923915	95938	3/14/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1670025	22052975163	95938	3/17/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2627479	22149163232	95938	3/17/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670522	22650002761	95938	3/18/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608133	22248580476	95938	3/21/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685088	22069858988	95938	3/21/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685237	22850114802	95938	3/23/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671610	22249869117	95938	3/24/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671626	22650130924	95938	3/24/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608130	22548727476	95938	3/28/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732693	22348592485	95938	4/3/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748771	22550706698	95938	4/7/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2107396	22443235302	95938	4/8/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237425	22644607831	95938	4/21/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607877	226449234464	95938	4/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845704	22651987119	95938	4/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890173	22251956203	95938	4/30/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2626980	22068564348	95938	5/5/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2956579	22652708365	95938	5/7/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2957086	22852703063	95938	5/9/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977228	22071423284	95938	5/23/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2973536	22749389876	95938	5/28/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060503	22753636769	95938	5/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091878	22353884451	95938	5/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216912	22755204307	95938	6/23/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3269942	22455209987	95938	6/26/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3277949	22555916421	95938	6/26/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3513918	22356144464	95938	8/1/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528425	22257386838	95938	8/1/2025	\$7,312.66	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3457646	22557189096	95938	8/7/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3458112	22757285248	95938	8/25/2025	\$7,937.66	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3528393	22658314815	95938	8/29/2025	\$2,862.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3528488	22257504137	95938	8/29/2025	\$7,312.66	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3665724	22078119415	95938	9/5/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3720474	22559775440	95938	9/5/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3837546	22077531117	95938	9/16/2025	\$11,900.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4052152	22562560966	95938	10/3/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3837543	22258010917	95938	11/4/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-4202626	22080688063	95938	11/4/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4021919	22361630511	95938	11/12/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4339998	22265100116	95938	11/25/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-914497	22714160939	95939	5/10/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-848339	22617903282	95939	6/6/2024	\$9,708.40	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-992501	22719286509	95939	7/18/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503726	22233439772	95939	9/20/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-992513	22416670314	95939	9/24/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1670320	22052975163	95939	10/27/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898791	22840424174	95939	11/10/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1817022	22736130233	95939	11/20/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491897	22414467926	95939	11/22/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2024424	22341617799	95939	12/12/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2025371	22241247150	95939	12/17/2024	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898216	22238859813	95939	12/19/2024	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2162936	22643758561	95939	1/15/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253796	22836855749	95939	1/15/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-966296	22817141024	95939	1/15/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	MCMC Services, LLC
DISP-2152723	22843530575	95939	1/16/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356145	22646186697	95939	1/23/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237928	22443823892	95939	1/30/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237944	22844586127	95939	1/30/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356133	22646295587	95939	1/31/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317356	22844586126	95939	2/3/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324112	22645904596	95939	2/6/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412156	22846296920	95939	2/6/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412169	22647134173	95939	2/6/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412177	22747047938	95939	2/6/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419655	22844522770	95939	2/10/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2420773	22444489677	95939	2/12/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375501	22846164385	95939	2/13/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419713	22847256641	95939	2/13/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465729	22547350965	95939	2/14/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1898992	20259394337	95939	2/24/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2465737	22647903058	95939	2/25/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536974	22148279392	95939	2/27/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608196	22247923915	95939	3/6/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607920	22548727476	95939	3/7/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627519	22149163232	95939	3/10/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608157	22248580476	95939	3/12/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2053095	22742624416	95939	3/14/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2626981	22068564348	95939	3/17/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670524	22650130924	95939	3/20/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608248	22348592484	95939	3/21/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671618	22249869117	95939	3/25/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237431	22644607831	95939	4/21/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2847746	22551342875	95939	4/28/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2848395	22651987119	95939	4/29/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890175	22251956203	95939	4/30/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956606	22553455042	95939	5/13/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2969060	22071423284	95939	5/16/2025	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001979	22072837086	95939	5/28/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091892	22353884451	95939	5/30/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026243	22653572517	95939	6/5/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060513	22753636769	95939	6/13/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2748785	22550706698	95939	6/19/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3216913	22755204307	95939	6/22/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278354	22555916421	95939	7/23/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-2977497	22552229253	95939	7/28/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3456240	22757285248	95939	7/28/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3458903	22557189096	95939	7/29/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3527824	22257386838	95939	8/4/2025	\$8,400.94	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3527850	22658314815	95939	8/19/2025	\$17,315.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3514884	22356144464	95939	9/3/2025	\$8,400.94	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3529143	22257504137	95939	9/4/2025	\$8,400.94	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3664019	22078119415	95939	9/5/2025	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721282	22559775440	95939	9/5/2025	\$2,646.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3842810	22258010917	95939	9/30/2025	\$16,075.01	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-4020991	22361630511	95939	10/6/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4202263	22080688063	95939	11/20/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-848371	22617903282	95941	6/6/2024	\$5,366.55	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1491864	22414467926	95941	8/5/2024	\$6,409.90	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503773	22833577311	95941	9/3/2024	\$38,459.40	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1612969	22235231286	95941	9/18/2024	\$38,459.40	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1503693	22233439772	95941	9/20/2024	\$12,819.80	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1669943	22052975163	95941	10/8/2024	\$12,819.80	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733906	22335859346	95941	10/17/2024	\$32,049.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1734553	22336463461	95941	10/17/2024	\$38,459.40	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760158	22137237027	95941	10/22/2024	\$19,229.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826149	22738652771	95941	10/24/2024	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826545	22417111938	95941	10/25/2024	\$57,689.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1817138	22736130233	95941	11/15/2024	\$11,179.35	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825342	22336104061	95941	11/19/2024	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851702	22539693367	95941	11/22/2024	\$73,984.68	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1761711	22436779390	95941	11/23/2024	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994529	22141311388	95941	12/6/2024	\$22,358.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024426	22241247150	95941	12/18/2024	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053083	22742624416	95941	12/31/2024	\$12,330.78	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2253787	22836855749	95941	1/14/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182602	22844079297	95941	1/15/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152716	22843530575	95941	1/16/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162924	22643758561	95941	1/16/2025	\$49,323.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355865	22646295587	95941	1/20/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356136	22646186697	95941	1/23/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375318	22846164385	95941	1/23/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237436	22443823892	95941	1/30/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237936	22844586127	95941	1/30/2025	\$36,992.84	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317350	22844586126	95941	2/4/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2323762	22645904596	95941	2/6/2025	\$98,646.24	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412160	22647134173	95941	2/6/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.

DISP No.	Claim Number	Code	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2412164	22747047938	95941	2/6/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419626	22444489677	95941	2/10/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411989	22846296920	95941	2/13/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412185	22847113443	95941	2/13/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419716	22846636199	95941	2/13/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465722	22547350965	95941	2/14/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465732	22647903058	95941	2/14/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2529620	22246304477	95941	2/21/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536968	22148279392	95941	2/21/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1898575	22840424174	95941	2/24/2025	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2419610	22844522770	95941	2/25/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419708	22847256641	95941	2/26/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608245	22348592484	95941	3/6/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607919	22548727476	95941	3/10/2025	\$49,323.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626973	22068564348	95941	3/10/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626984	22149163232	95941	3/11/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685235	22850114802	95941	3/20/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685245	22064731364	95941	3/21/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671621	22650130924	95941	3/23/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670525	22650002761	95941	3/25/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685087	22069858988	95941	3/25/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671606	22249869117	95941	3/28/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748620	22550706698	95941	4/7/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237424	22644607831	95941	4/21/2025	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2847167	22551342875	95941	4/29/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890174	22251956203	95941	4/30/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956577	22652708365	95941	5/7/2025	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956595	22553455042	95941	5/12/2025	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3007305	22553455043	95941	5/16/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026241	22653572517	95941	5/17/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2608286	22247923915	95941	6/19/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3091877	22353884451	95941	7/7/2025	\$24,661.56	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3277950	22555916421	95941	7/23/2025	\$40,000.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3269941	22455209987	95941	7/24/2025	\$933.10	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3457635	22557189096	95941	7/28/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528869	22257504137	95941	8/1/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3513660	22356144464	95941	8/5/2025	\$8,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3457521	22757285248	95941	8/7/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3529065	22257386838	95941	9/4/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3721525	22559775440	95941	9/5/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3844107	22077531117	95941	10/3/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3663508	22078119415	95941	10/15/2025	\$2,400.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3923993	22461748815	95941	10/24/2025	\$32,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237947	22342490541	95955	1/30/2025	\$8,599.50	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2109526	22443235302	95955	4/8/2025	\$7,309.58	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3277944	22075139592	95955	7/23/2025	\$7,309.58	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization

Total: **\$4,653,243.43**

EXHIBIT B

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2419658	22844522770	51785	1/15/2025	2/10/2025	12/30/2024	DISP-2024429	16	\$2,497.91	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465736	22847903058	51785	1/27/2025	2/18/2025	1/15/2025	DISP-968265	12	\$2,497.91	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1824699	22417111938	92653	9/23/2024	12/4/2024	9/18/2024	DISP-1612022	5	\$1,208.90	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851703	22538622076	92653	9/27/2024	11/23/2024	9/18/2024	DISP-1612022	9	\$1,098.13	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182598	22842459316	92653	11/29/2024	1/10/2025	11/23/2024	DISP-1851703	6	\$1,098.13	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412180	22847113443	92653	1/14/2025	2/26/2025	12/4/2024	DISP-1824699	41	\$1,098.13	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732697	22348592485	92653	3/10/2025	4/1/2025	2/26/2025	DISP-2412180	12	\$1,098.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3306153	22152860320	95720	5/29/2025	6/27/2025	5/16/2025	DISP-2890555	13	\$6,221.22	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1763006	22836533011	95813	9/10/2024	10/27/2024	8/5/2024	DISP-1503765	36	\$6,221.22	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491889	22414467926	95861	7/1/2024	11/22/2024	6/30/2024	DISP-1111498	1	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503715	22233439772	95861	7/4/2024	9/25/2024	6/30/2024	DISP-1111498	4	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1670784	22052975163	95861	8/16/2024	10/15/2024	7/25/2024	DISP-1037220	22	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1734808	22336463461	95861	9/5/2024	10/16/2024	7/25/2024	DISP-1037220	42	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1763008	22137237027	95861	9/10/2024	10/27/2024	7/25/2024	DISP-1037220	47	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1843538	22055176348	95861	9/26/2024	11/19/2024	9/25/2024	DISP-1503715	1	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2162935	22643758661	95861	11/26/2024	1/15/2025	11/23/2024	DISP-1851336	3	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317354	22844586126	95861	12/26/2024	2/3/2025	11/27/2024	DISP-2024427	9	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324108	22645904596	95861	12/27/2024	2/6/2025	12/17/2024	DISP-2024427	10	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356134	22646295587	95861	1/3/2025	2/25/2025	12/17/2024	DISP-2024427	17	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356143	22646186697	95861	1/3/2025	1/23/2025	12/17/2024	DISP-2024427	17	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411997	22846296920	95861	1/14/2025	2/5/2025	12/17/2024	DISP-2024427	28	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412174	22747047938	95861	1/14/2025	2/6/2025	12/17/2024	DISP-2024427	28	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465728	22547350965	95861	1/27/2025	2/14/2025	1/23/2025	DISP-2356143	4	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465735	22647903058	95861	1/27/2025	2/14/2025	1/23/2025	DISP-2356143	4	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608195	22247923915	95861	2/19/2025	3/6/2025	2/14/2025	DISP-2465735	5	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626808	22068564348	95861	2/22/2025	3/7/2025	2/14/2025	DISP-2465735	8	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627480	22149163232	95861	2/22/2025	3/10/2025	2/14/2025	DISP-2465735	8	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670526	22650130924	95861	2/28/2025	3/24/2025	2/14/2025	DISP-2356134	3	\$7,769.59	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2977488	22552229253	95861	4/10/2025	5/28/2025	3/24/2025	DISP-2670526	17	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216911	22755204307	95861	5/15/2025	6/23/2025	3/24/2025	DISP-2670526	52	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3218276	22555093534	95861	5/15/2025	6/23/2025	3/24/2025	DISP-2670526	52	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3269943	22455209987	95861	5/22/2025	6/27/2025	3/24/2025	DISP-2670526	59	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278353	22555916421	95861	5/23/2025	6/26/2025	3/24/2025	DISP-2670526	60	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3456257	22757285248	95861	6/18/2025	7/28/2025	5/28/2025	DISP-2977488	21	\$7,769.59	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3459250	22557189096	95861	6/18/2025	8/7/2025	5/28/2025	DISP-2977488	21	\$7,769.59	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-2152719	22843530575	95868	11/25/2024	1/16/2025	11/7/2024	DISP-918054	18	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253792	22836855749	95868	12/13/2024	1/2/2025	11/7/2024	DISP-918054	36	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356142	22646186697	95868	1/3/2025	1/23/2025	1/2/2025	DISP-2253792	1	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670521	22650130924	95868	2/28/2025	3/17/2025	1/23/2025	DISP-2356142	36	\$5,633.95	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3001941	22553455043	95868	4/15/2025	5/23/2025	3/17/2025	DISP-2670521	29	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001962	22072837086	95868	4/15/2025	5/17/2025	3/17/2025	DISP-2670521	29	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091888	22353884451	95868	4/28/2025	5/29/2025	3/17/2025	DISP-2670521	42	\$5,633.95	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3529605	22658314815	95868	6/30/2025	9/3/2025	5/29/2025	DISP-3091888	32	\$5,100.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3722110	22559775440	95868	7/28/2025	9/5/2025	5/29/2025	DISP-3091888	60	\$3,619.33	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1816460	22736130233	95870	9/20/2024	11/23/2024	9/11/2024	DISP-718069	9	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898395	20259394337	95870	10/7/2024	4/21/2025	9/25/2024	DISP-1045529	12	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898396	22238859813	95870	10/7/2024	12/20/2024	9/25/2024	DISP-1045529	12	\$9,122.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898975	22840424174	95870	10/7/2024	11/10/2024	9/25/2024	DISP-1045529	12	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994563	22141311388	95870	10/29/2024	12/6/2024	10/26/2024	DISP-1758187	3	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2025423	22241247150	95870	11/4/2024	12/24/2024	10/26/2024	DISP-1758187	9	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237429	22644607831	95870	12/10/2024	4/21/2025	12/6/2024	DISP-1994563	4	\$4,561.17	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253790	22836855749	95870	12/13/2024	1/2/2025	12/6/2024	DISP-1994563	7	\$4,561.17	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375500	22846164385	95870	1/7/2025	1/23/2025	12/31/2024	DISP-2253790	7	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412163	22647134173	95870	1/14/2025	2/6/2025	12/31/2024	DISP-2253790	14	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419711	22847256641	95870	1/15/2025	2/26/2025	12/31/2024	DISP-2253790	15	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607918	22248580476	95870	2/19/2025	3/7/2025	2/6/2025	DISP-2412163	13	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671614	22249869117	95870	2/28/2025	3/28/2025	2/26/2025	DISP-2419711	2	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2758893	22550706698	95870	3/13/2025	4/8/2025	3/7/2025	DISP-2607918	6	\$9,122.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845691	22350062937	95870	3/26/2025	4/29/2025	3/7/2025	DISP-2607918	19	\$4,561.17	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3030102	22653572517	95870	4/17/2025	6/21/2025	4/8/2025	DISP-2758893	9	\$9,122.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3663252	22078119415	95870	7/18/2025	9/5/2025	6/21/2025	DISP-3030102	27	\$5,706.28	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3720706	22559775440	95870	7/28/2025	9/5/2025	8/21/2025	DISP-3030102	37	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2536969	22148279392	95885	2/6/2025	2/27/2025	12/31/2024	DISP-2024931	37	\$13,055.18	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2890176	22251956203	95885	3/31/2025	6/11/2025	2/27/2025	DISP-2536969	32	\$13,055.18	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2182606	22844079297	95886	11/29/2024	1/10/2025	11/19/2024	DISP-1825567	10	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237927	22443823892	95886	12/10/2024	1/30/2025	11/19/2024	DISP-1825567	21	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237939	22844586127	95886	12/10/2024	1/30/2025	11/19/2024	DISP-1825567	21	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419723	22846636199	95886	1/15/2025	2/12/2025	11/19/2024	DISP-1825567	57	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419628	22444489677	95886	1/15/2025	2/18/2025	11/19/2024	DISP-1825567	57	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419649	22844522770	95886	1/15/2025	2/12/2025	11/19/2024	DISP-1825567	57	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608132	22348592484	95886	2/19/2025	3/13/2025	2/18/2025	DISP-2419628	1	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608249	22548727476	95886	2/19/2025	3/25/2025	2/18/2025	DISP-2419628	1	\$12,993.28	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670529	22650002761	95886	2/28/2025	3/24/2025	2/18/2025	DISP-2419628	10	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685232	22069858988	95886	3/3/2025	3/25/2025	2/18/2025	DISP-2419628	13	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2685243	22850114802	95886	3/3/2025	3/23/2025	2/18/2025	DISP-2419628	13	\$6,496.64	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2977227	22071423284	95886	4/10/2025	5/28/2025	3/25/2025	DISP-2685232	16	\$6,678.94	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3515034	22356144464	95886	6/27/2025	8/1/2025	5/28/2025	DISP-2977227	30	\$566.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851101	22538622076	95887	9/27/2024	11/23/2024	9/23/2024	DISP-1146355	4	\$7,606.54	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2685248	22064731364	95887	3/3/2025	3/14/2025	2/26/2025	DISP-2529625	5	\$3,339.47	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182609	22844079297	95907	11/29/2024	1/14/2025	10/25/2024	DISP-1825738	35	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237941	22844586127	95907	12/10/2024	1/30/2025	10/25/2024	DISP-1825738	46	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419654	22844522770	95907	1/15/2025	2/12/2025	10/25/2024	DISP-1825738	82	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419724	22846636199	95907	1/15/2025	2/12/2025	10/25/2024	DISP-1825738	82	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670533	22650002761	95907	2/28/2025	3/25/2025	2/26/2025	DISP-2529624	2	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685242	22850114802	95907	3/3/2025	3/26/2025	2/26/2025	DISP-2529624	5	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685234	22069858988	95907	3/3/2025	3/23/2025	2/26/2025	DISP-2529624	5	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685246	22064731364	95907	3/3/2025	3/25/2025	2/26/2025	DISP-2529624	5	\$2,717.44	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2957079	22035849365	95907	4/9/2025	5/27/2025	3/26/2025	DISP-2685242	14	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216915	22651454339	95907	5/15/2025	6/27/2025	3/26/2025	DISP-2685242	50	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3514754	22356144464	95907	6/27/2025	8/4/2025	5/27/2025	DISP-2957079	31	\$2,717.44	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2237929	22443823892	95908	12/10/2024	1/30/2025	11/23/2024	DISP-1851064	17	\$2,293.20	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536973	22148279392	95908	2/6/2025	2/24/2025	12/30/2024	DISP-2024422	38	\$2,293.20	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2890177	22251956203	95908	3/31/2025	6/27/2025	2/24/2025	DISP-2536973	35	\$3,870.92	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2608247	22348592484	95909	2/19/2025	3/21/2025	2/12/2025	DISP-2419635	7	\$5,201.89	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2969059	22071423284	95909	4/10/2025	5/16/2025	3/21/2025	DISP-2608247	20	\$2,231.86	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3457200	22657544591	95909	6/18/2025	7/28/2025	5/16/2025	DISP-2969059	33	\$849.15	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343198	22129855904	95937	5/16/2024	6/19/2024	5/14/2024	DISP-1037211	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343213	22429243808	95937	5/16/2024	7/28/2024	5/14/2024	DISP-1037211	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1371433	NA780262405025988 00	95937	5/23/2024	8/11/2024	5/14/2024	DISP-1037211	9	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1406316	22131533373	95937	6/6/2024	8/15/2024	5/14/2024	DISP-1037211	23	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491879	22414467926	95937	7/1/2024	11/22/2024	6/18/2024	DISP-1338661	13	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503706	22233439772	95937	7/4/2024	9/19/2024	7/2/2024	DISP-1111499	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503741	22833667576	95937	7/4/2024	9/20/2024	7/2/2024	DISP-1111499	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503794	22833577311	95937	7/4/2024	8/5/2024	7/2/2024	DISP-1111499	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1612642	222352331286	95937	8/2/2024	9/20/2024	7/2/2024	DISP-1111499	31	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1673307	22052975163	95937	8/16/2024	10/2/2024	8/15/2024	DISP-1406316	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1732926	22336463461	95937	9/5/2024	10/16/2024	8/15/2024	DISP-1406316	21	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1732928	22335859346	95937	9/5/2024	10/15/2024	8/15/2024	DISP-1406316	21	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1755759	22436779390	95937	9/10/2024	11/23/2024	8/15/2024	DISP-1406316	26	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760077	22836533011	95937	9/10/2024	10/21/2024	8/15/2024	DISP-1406316	26	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1762954	22137237027	95937	9/10/2024	10/22/2024	8/15/2024	DISP-1406316	26	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825159	22738652771	95937	9/23/2024	11/19/2024	9/20/2024	DISP-992261	3	\$6,957.73	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825365	22417111938	95937	9/23/2024	11/18/2024	9/20/2024	DISP-992261	3	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825758	22336104061	95937	9/23/2024	11/20/2024	9/20/2024	DISP-992261	3	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1844325	22055176348	95937	9/26/2024	11/20/2024	9/24/2024	DISP-992316	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852254	22539693367	95937	9/27/2024	11/23/2024	9/24/2024	DISP-992316	3	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852799	22538622076	95937	9/27/2024	10/31/2024	9/24/2024	DISP-992316	3	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898774	20259394337	95937	10/7/2024	11/24/2024	10/2/2024	DISP-1673307	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1899485	22840424174	95937	10/7/2024	11/5/2024	10/2/2024	DISP-1673307	7	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994052	22141311388	95937	10/29/2024	12/9/2024	10/22/2024	DISP-1762954	5	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024421	22341617799	95937	11/4/2024	12/27/2024	10/31/2024	DISP-1852799	4	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053089	22742624416	95937	11/7/2024	1/2/2025	11/5/2024	DISP-1899485	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2109522	22443235302	95937	11/19/2024	4/8/2025	11/18/2024	DISP-1825365	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152720	22843530575	95937	11/25/2024	1/16/2025	11/24/2024	DISP-1898774	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162932	22643758561	95937	11/26/2024	1/15/2025	11/24/2024	DISP-1898774	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182599	22842459316	95937	11/29/2024	1/15/2025	11/27/2024	DISP-1898187	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182604	22844079297	95937	11/29/2024	1/10/2025	11/27/2024	DISP-1898187	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237426	22644607831	95937	12/10/2024	4/21/2025	12/9/2024	DISP-1994052	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237925	22443823892	95937	12/10/2024	1/30/2025	12/9/2024	DISP-1994052	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237940	22844586127	95937	12/10/2024	1/30/2025	12/9/2024	DISP-1994052	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237949	22342490541	95937	12/10/2024	1/30/2025	12/9/2024	DISP-1994052	1	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253791	22836855749	95937	12/13/2024	12/31/2024	12/9/2024	DISP-1994052	4	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317353	22844586126	95937	12/26/2024	2/3/2025	12/17/2024	DISP-2025421	9	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324105	22645904596	95937	12/27/2024	2/6/2025	12/17/2024	DISP-2025421	10	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355868	22846295587	95937	1/3/2025	1/22/2025	1/2/2025	DISP-2053089	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356138	22846186697	95937	1/3/2025	3/10/2025	1/2/2025	DISP-2053089	1	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375319	22846164385	95937	1/7/2025	1/23/2025	1/2/2025	DISP-2053089	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411996	22846296920	95937	1/14/2025	2/6/2025	1/2/2025	DISP-2053089	12	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412162	22647134173	95937	1/14/2025	2/14/2025	1/2/2025	DISP-2053089	12	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412173	22747047938	95937	1/14/2025	2/7/2025	1/2/2025	DISP-2053089	12	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412181	22847113443	95937	1/14/2025	2/6/2025	1/2/2025	DISP-2053089	12	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419722	22846636199	95937	1/15/2025	2/12/2025	1/2/2025	DISP-2053089	13	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419629	22444489677	95937	1/15/2025	2/25/2025	1/2/2025	DISP-2053089	13	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419712	22847256641	95937	1/15/2025	2/26/2025	1/2/2025	DISP-2053089	13	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419728	22844522770	95937	1/15/2025	2/12/2025	1/2/2025	DISP-2053089	13	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465723	22547350965	95937	1/27/2025	2/13/2025	1/23/2025	DISP-2375319	4	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465733	22647903058	95937	1/27/2025	2/14/2025	1/23/2025	DISP-2375319	4	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2529618	22246304477	95937	2/5/2025	2/26/2025	2/3/2025	DISP-2317353	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-2536967	22148279392	95937	2/6/2025	2/21/2025	2/6/2025	DISP-2317353	3	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607917	22248580476	95937	2/19/2025	3/6/2025	2/14/2025	DISP-2465733	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607923	22548727476	95937	2/19/2025	3/21/2025	2/14/2025	DISP-2465733	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608135	22247923915	95937	2/19/2025	3/19/2025	2/14/2025	DISP-2465733	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608246	22348592484	95937	2/19/2025	3/7/2025	2/14/2025	DISP-2465733	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626807	22068564348	95937	2/22/2025	3/17/2025	2/21/2025	DISP-2536967	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626809	22149163232	95937	2/22/2025	3/10/2025	2/21/2025	DISP-2536967	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670520	22650130924	95937	2/28/2025	3/20/2025	2/26/2025	DISP-2529618 DISP-2419712	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670530	22650002761	95937	2/28/2025	3/21/2025	2/26/2025	DISP-2529618 DISP-2419712	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671613	22249869117	95937	2/28/2025	3/24/2025	2/26/2025	DISP-2529618 DISP-2419712	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685240	22850114802	95937	3/3/2025	3/25/2025	2/26/2025	DISP-2529618 DISP-2419712	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685089	22069858988	95937	3/3/2025	3/25/2025	2/26/2025	DISP-2529618 DISP-2419712	5	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732696	22348592485	95937	3/10/2025	4/7/2025	3/10/2025	DISP-2626809	0	\$4,484.49	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748772	22550706698	95937	3/12/2025	4/3/2025	3/10/2025	DISP-2356138 DISP-2626809	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845684	22346901967	95937	3/26/2025	4/29/2025	3/25/2025	DISP-2685089 DISP-2685240	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890178	22251956203	95937	3/31/2025	4/30/2025	3/25/2025	DISP-2685089 DISP-2685240	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956597	22553455042	95937	4/9/2025	5/13/2025	4/8/2025	DISP-2109522	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2957076	22035849365	95937	4/9/2025	5/23/2025	4/8/2025	DISP-2109522	1	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2974479	22749389876	95937	4/10/2025	5/30/2025	4/8/2025	DISP-2109522	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977226	22071423284	95937	4/10/2025	5/16/2025	4/8/2025	DISP-2109522	2	\$4,484.49	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977484	22552229253	95937	4/10/2025	7/29/2025	4/8/2025	DISP-2109522	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001956	22072837086	95937	4/15/2025	5/17/2025	4/8/2025	DISP-2109522	7	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3029706	22653572517	95937	4/17/2025	5/17/2025	4/8/2025	DISP-2109522	9	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091879	22353884451	95937	4/28/2025	5/30/2025	4/8/2025	DISP-2109522	20	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3218275	22555093534	95937	5/15/2025	6/30/2025	5/13/2025	DISP-2956597	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216914	22651454339	95937	5/15/2025	6/22/2025	5/13/2025	DISP-2956597	2	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278355	22555916421	95937	5/23/2025	7/23/2025	5/17/2025	DISP-3001956 DISP-3029706	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3277945	22075139592	95937	5/23/2025	6/26/2025	5/17/2025	DISP-3001956 DISP-3029706	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3316162	22756486572	95937	5/29/2025	6/27/2025	5/23/2025	DISP-2957076 DISP-3007307	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3455689	22657544591	95937	6/18/2025	7/28/2025	6/12/2025	DISP-3060506	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3456768	22757285248	95937	6/18/2025	8/7/2025	6/12/2025	DISP-3060506	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3458749	22557189096	95937	6/18/2025	7/28/2025	6/12/2025	DISP-3060506	6	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3514465	22356144464	95937	6/27/2025	8/5/2025	6/26/2025	DISP-3277945	1	\$3,112.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3531463	22257504137	95937	6/30/2025	9/5/2025	6/27/2025	DISP-3316162	3	\$4,484.49	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3529144	22658314815	95937	6/30/2025	8/1/2025	6/27/2025	DISP-3316162	3	\$619.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3664015	22078119415	95937	7/18/2025	9/5/2025	6/30/2025	DISP-3218275	18	\$557.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721960	22559775440	95937	7/28/2025	9/24/2025	7/24/2025	DISP-3269944	4	\$619.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3841346	22077531117	95937	8/13/2025	11/14/2025	8/7/2025	DISP-3456768	6	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-914536	22714160939	95938	1/12/2024	10/15/2024	12/22/2023	DISP-360091	21	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-966291	22817141024	95938	2/1/2024	7/31/2024	12/22/2023	DISP-360091	41	\$8,746.30	Bromedicon, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-992251	22416670314	95938	2/7/2024	7/17/2024	12/22/2023	DISP-360091	47	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-992306	22719286509	95938	2/7/2024	8/5/2024	12/22/2023	DISP-360091	47	\$8,746.30	BROMEDICON, LLC	HIGHMARK	MCMC Services, LLC
DISP-1037207	22221528553	95938	2/20/2024	5/27/2024	12/22/2023	DISP-360091	60	\$8,746.30	BROMEDICON, LLC	HIGHMARK	IMPROVe Health
DISP-1053526	22820639402	95938	2/23/2024	8/29/2024	2/22/2024	DISP-848289	1	\$8,746.30	Bromedicon, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1111501	22122421292	95938	3/6/2024	7/10/2024	2/22/2024	DISP-848289	13	\$8,746.30	Bromedicon, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1303798	22626305199	95938	5/3/2024	7/13/2024	2/22/2024	DISP-848289	71	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1338654	22042317633	95938	5/15/2024	6/19/2024	2/22/2024	DISP-848289	83	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1338866	22129855905	95938	5/15/2024	8/26/2024	2/22/2024	DISP-848289	83	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343160	22529010348	95938	5/16/2024	6/24/2024	2/22/2024	DISP-848289	84	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343189	22129855904	95938	5/16/2024	6/25/2024	2/22/2024	DISP-848289	84	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1343206	22429243808	95938	5/16/2024	7/28/2024	2/22/2024	DISP-848289	84	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1371429	NA780262405025988 00	95938	5/23/2024	8/27/2024	5/20/2024	DISP-416039	3	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1406308	22131533373	95938	6/6/2024	7/25/2024	5/27/2024	DISP-1037207	10	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491870	22414467926	95938	7/1/2024	8/21/2024	5/27/2024	DISP-1037207	35	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503702	22233439772	95938	7/4/2024	9/19/2024	5/27/2024	DISP-1037207	38	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503733	22833667576	95938	7/4/2024	9/18/2024	5/27/2024	DISP-1037207	38	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503780	22833577311	95938	7/4/2024	7/31/2024	5/27/2024	DISP-1037207	38	\$8,746.30	BROMEDICON, LLC	HIGHMARK	Federal Hearings and Appeals Services, Inc.
DISP-1606356	22333030702	95938	7/31/2024	9/14/2024	7/31/2024	DISP-1503780	0	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1670025	22052975163	95938	8/16/2024	3/17/2025	7/31/2024	DISP-1503780	16	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733315	22335859346	95938	9/5/2024	10/16/2024	8/21/2024	DISP-1491870	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733620	22336463461	95938	9/5/2024	10/16/2024	8/21/2024	DISP-1491870	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760164	22137237027	95938	9/10/2024	10/22/2024	8/21/2024	DISP-1491870	20	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1761756	22836533011	95938	9/10/2024	10/25/2024	8/21/2024	DISP-1491870	20	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-1758059	22436779390	95938	9/10/2024	11/20/2024	8/21/2024	DISP-1491870	20	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1816626	22736130233	95938	9/20/2024	11/14/2024	9/19/2024	DISP-1503702	1	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826540	22417111938	95938	9/23/2024	11/17/2024	9/19/2024	DISP-1503702	4	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1844027	22055176348	95938	9/26/2024	10/25/2024	9/19/2024	DISP-1503702	7	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1852059	22539693367	95938	9/27/2024	10/28/2024	9/19/2024	DISP-1503702	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1854105	22538622076	95938	9/27/2024	10/31/2024	9/19/2024	DISP-1503702	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898976	20259394337	95938	10/7/2024	1/29/2025	9/19/2024	DISP-1503702	18	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898790	22840424174	95938	10/7/2024	11/10/2024	9/19/2024	DISP-1503702	18	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994442	22141311388	95938	10/29/2024	12/5/2024	10/28/2024	DISP-1852059	1	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2025370	22241247150	95938	11/4/2024	12/31/2024	10/31/2024	DISP-1854105	4	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053087	22742624416	95938	11/7/2024	12/31/2024	10/31/2024	DISP-1854105	7	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2107396	22443235302	95938	11/19/2024	4/8/2025	11/17/2024	DISP-1826540	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2152717	22843530575	95938	11/25/2024	1/16/2025	11/20/2024	DISP-1758059	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162927	22643758561	95938	11/26/2024	1/15/2025	11/20/2024	DISP-1758059	6	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182603	22844079297	95938	11/29/2024	1/10/2025	11/20/2024	DISP-1758059	9	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237425	22644607831	95938	12/10/2024	4/21/2025	12/5/2024	DISP-1994442	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237438	22443823892	95938	12/10/2024	1/30/2025	12/5/2024	DISP-1994442	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237938	22844586127	95938	12/10/2024	1/30/2025	12/5/2024	DISP-1994442	5	\$10,909.93	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237946	22342490541	95938	12/10/2024	1/30/2025	12/5/2024	DISP-1994442	5	\$10,909.93	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253789	22836855749	95938	12/13/2024	12/30/2024	12/5/2024	DISP-1994442	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317351	22844586126	95938	12/26/2024	2/3/2025	12/18/2024	DISP-2025369	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2323768	22645904596	95938	12/27/2024	2/6/2025	12/18/2024	DISP-2025369	9	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355866	22646295587	95938	1/3/2025	1/22/2025	12/31/2024	DISP-2025370 DISP-2053087	3	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356137	22646186697	95938	1/3/2025	3/10/2025	12/31/2024	DISP-2025370 DISP-2053087	3	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375315	22846164385	95938	1/7/2025	2/12/2025	12/31/2024	DISP-2025370 DISP-2053087	7	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412000	22846296920	95938	1/14/2025	2/6/2025	12/31/2024	DISP-2025370 DISP-2053087	14	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412161	22647134173	95938	1/14/2025	2/6/2025	12/31/2024	DISP-2025370 DISP-2053087	14	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412172	22747047938	95938	1/14/2025	2/6/2025	12/31/2024	DISP-2025370 DISP-2053087	14	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412178	22847113443	95938	1/14/2025	2/24/2025	12/31/2024	DISP-2025370 DISP-2053087	14	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419709	22847256641	95938	1/15/2025	2/26/2025	12/31/2024	DISP-2025370 DISP-2053087	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419729	22844522770	95938	1/15/2025	2/12/2025	12/31/2024	DISP-2025370 DISP-2053087	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2420764	22444489677	95938	1/15/2025	2/10/2025	12/31/2024	DISP-2025370 DISP-2053087	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419719	22846636199	95938	1/15/2025	2/12/2025	12/31/2024	DISP-2025370 DISP-2053087	15	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465726	22547350965	95938	1/27/2025	2/13/2025	1/22/2025	DISP-2355866	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465734	22647903058	95938	1/27/2025	2/14/2025	1/22/2025	DISP-2355866	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536966	22148279392	95938	2/6/2025	2/24/2025	2/3/2025	DISP-2317351	3	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607877	226449234464	95938	2/19/2025	4/29/2025	2/14/2025	DISP-2465734	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608133	22248580476	95938	2/19/2025	3/21/2025	2/14/2025	DISP-2465734	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607921	22247923915	95938	2/19/2025	3/14/2025	2/14/2025	DISP-2465734	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608130	22548727476	95938	2/19/2025	3/28/2025	2/14/2025	DISP-2465734	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608161	22348592484	95938	2/19/2025	3/6/2025	2/14/2025	DISP-2465734	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626980	22068564348	95938	2/22/2025	5/5/2025	2/14/2025	DISP-2465734	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627406	22149343815	95938	2/22/2025	3/12/2025	2/14/2025	DISP-2465734	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627479	22149163232	95938	2/22/2025	3/17/2025	2/14/2025	DISP-2465734	8	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671610	22249869117	95938	2/28/2025	3/24/2025	2/26/2025	DISP-2419709	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671626	22650130924	95938	2/28/2025	3/24/2025	2/26/2025	DISP-2419709	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670522	22650002761	95938	2/28/2025	3/18/2025	2/26/2025	DISP-2419709	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685088	22069858988	95938	3/3/2025	3/21/2025	2/26/2025	DISP-2419709	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685237	22850114802	95938	3/3/2025	3/23/2025	2/26/2025	DISP-2419709	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2732693	22348592485	95938	3/10/2025	4/3/2025	3/10/2025	DISP-2356137	0	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748771	22550706698	95938	3/12/2025	4/7/2025	3/10/2025	DISP-2356137	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2845704	22651987119	95938	3/26/2025	4/29/2025	3/24/2025	DISP-2671610 DISP-2671626	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890173	22251956203	95938	3/31/2025	4/30/2025	3/28/2025	DISP-2608130	3	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956579	22652708365	95938	4/9/2025	5/7/2025	4/8/2025	DISP-2107396	1	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2957086	22852703063	95938	4/9/2025	5/9/2025	4/8/2025	DISP-2107396	1	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977228	22071423284	95938	4/10/2025	5/23/2025	4/8/2025	DISP-2107396	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2973536	22749389876	95938	4/10/2025	5/28/2025	4/8/2025	DISP-2107396	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060503	22753636769	95938	4/22/2025	5/29/2025	4/8/2025	DISP-2107396	14	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091878	22353884451	95938	4/28/2025	5/29/2025	4/8/2025	DISP-2107396	20	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216912	22755204307	95938	5/15/2025	6/23/2025	5/13/2025	DISP-2956601 DISP-2977777	2	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3269942	22455209987	95938	5/22/2025	6/26/2025	5/17/2025	DISP-3030101	5	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3277949	22555916421	95938	5/23/2025	6/26/2025	5/17/2025	DISP-2977777 DISP-3030101	6	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3458112	22757285248	95938	6/18/2025	8/25/2025	5/29/2025	DISP-3060503 DISP-3091878	20	\$7,937.66	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3457646	22557189096	95938	6/18/2025	8/7/2025	5/29/2025	DISP-3060503 DISP-3091878	20	\$8,746.30	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3513918	22356144464	95938	6/27/2025	8/1/2025	6/26/2025	DISP-3269942 DISP-3277943 DISP-3277949	1	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528393	22658314815	95938	6/30/2025	8/29/2025	6/27/2025	DISP-3313462	3	\$2,862.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3528425	22257386838	95938	6/30/2025	8/1/2025	6/27/2025	DISP-3313462	3	\$7,312.66	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528488	22257504137	95938	6/30/2025	8/29/2025	6/27/2025	DISP-3313462	3	\$7,312.66	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3665724	22078119415	95938	7/18/2025	9/5/2025	6/27/2025	DISP-3313462	21	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3720474	22559775440	95938	7/28/2025	9/5/2025	7/19/2025	DISP-3001955	9	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3837543	22258010917	95938	8/13/2025	11/4/2025	8/7/2025	DISP-3457646	6	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3837546	22077531117	95938	8/13/2025	9/16/2025	8/7/2025	DISP-3457646	6	\$11,900.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-848339	22617903282	95939	12/20/2023	6/6/2024	11/15/2023	DISP-360104	35	\$9,708.40	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-914497	22714160939	95939	1/12/2024	5/10/2024	11/15/2023	DISP-360104	58	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-966296	22817141024	95939	2/1/2024	1/15/2025	11/15/2023	DISP-360104	78	\$9,843.83	BROMEDICON, LLC	HIGHMARK	MCMC Services, LLC
DISP-992513	22416670314	95939	2/7/2024	9/24/2024	11/15/2023	DISP-360104	84	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-992501	22719286509	95939	6/28/2024	7/18/2024	6/6/2024	DISP-848339	22	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1491897	22414467926	95939	7/1/2024	11/22/2024	6/6/2024	DISP-848339	25	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503726	22233439772	95939	7/4/2024	9/20/2024	6/6/2024	DISP-848339	28	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1670320	22052975163	95939	8/16/2024	10/27/2024	6/6/2024	DISP-848339	71	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1817022	22736130233	95939	9/20/2024	11/20/2024	9/12/2024	DISP-1343232	8	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898992	20259394337	95939	10/7/2024	2/24/2025	10/3/2024	DISP-1037229	4	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898216	22238859813	95939	10/7/2024	12/19/2024	10/3/2024	DISP-1037229	4	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898791	22840424174	95939	10/7/2024	11/10/2024	10/3/2024	DISP-1037229	4	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024424	22341617799	95939	11/4/2024	12/12/2024	10/27/2024	DISP-1670320	8	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2025371	22241247150	95939	11/4/2024	12/17/2024	10/27/2024	DISP-1670320	8	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053095	22742624416	95939	11/7/2024	3/14/2025	10/27/2024	DISP-1670320	11	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2152723	22843530575	95939	11/25/2024	1/16/2025	11/23/2024	DISP-1851066	2	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162936	22643758561	95939	11/26/2024	1/15/2025	11/23/2024	DISP-1851066	3	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237431	22644607831	95939	12/10/2024	4/21/2025	11/23/2024	DISP-1851066	17	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237928	22443823892	95939	12/10/2024	1/30/2025	11/23/2024	DISP-1851066	17	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237944	22844586127	95939	12/10/2024	1/30/2025	11/23/2024	DISP-1851066	17	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253796	22836855749	95939	12/13/2024	1/15/2025	12/12/2024	DISP-2024424	1	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317356	22844586126	95939	12/26/2024	2/3/2025	12/19/2024	DISP-1898216	7	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2324112	22645904596	95939	12/27/2024	2/6/2025	12/19/2024	DISP-1898216	8	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356133	22646295587	95939	1/3/2025	1/31/2025	12/19/2024	DISP-1898216	15	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356145	22646186697	95939	1/3/2025	1/23/2025	12/19/2024	DISP-1898216	15	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375501	22846164385	95939	1/7/2025	2/13/2025	12/19/2024	DISP-1898216	19	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412156	22846296920	95939	1/14/2025	2/6/2025	12/19/2024	DISP-1898216	26	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412177	22747047938	95939	1/14/2025	2/6/2025	12/19/2024	DISP-1898216	26	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412169	22647134173	95939	1/14/2025	2/6/2025	12/19/2024	DISP-1898216	26	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419655	22844522770	95939	1/15/2025	2/10/2025	12/19/2024	DISP-1898216	27	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419713	22847256641	95939	1/15/2025	2/13/2025	12/19/2024	DISP-1898216	27	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2420773	22444489677	95939	1/15/2025	2/12/2025	1/15/2025	DISP-966296	0	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465729	22547350965	95939	1/27/2025	2/14/2025	1/23/2025	DISP-2356145	4	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2465737	22647903058	95939	1/27/2025	2/25/2025	1/23/2025	DISP-2356145	4	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536974	22148279392	95939	2/6/2025	2/27/2025	2/3/2025	DISP-2317356	3	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2607920	22548727476	95939	2/19/2025	3/7/2025	2/14/2025	DISP-2465729	5	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608157	22248580476	95939	2/19/2025	3/12/2025	2/14/2025	DISP-2465729	5	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608196	22247923915	95939	2/19/2025	3/6/2025	2/14/2025	DISP-2465729	5	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2608248	22348592484	95939	2/19/2025	3/21/2025	2/14/2025	DISP-2465729	5	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2626981	22068564348	95939	2/22/2025	3/17/2025	2/14/2025	DISP-2465729	8	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2627519	22149163232	95939	2/22/2025	3/10/2025	2/14/2025	DISP-2465729	8	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670524	22650130924	95939	2/28/2025	3/20/2025	2/27/2025	DISP-2536974	1	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671618	22249869117	95939	2/28/2025	3/25/2025	2/27/2025	DISP-2536974	1	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748785	22550706698	95939	3/12/2025	6/19/2025	3/10/2025	DISP-2627519	2	\$9,843.83	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2847746	22551342875	95939	3/26/2025	4/28/2025	3/26/2025	DISP-2671618	1	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2848395	22651987119	95939	3/26/2025	4/29/2025	3/25/2025	DISP-2671618	1	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890175	22251956203	95939	3/31/2025	4/30/2025	3/25/2025	DISP-2671618	6	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956806	22553455042	95939	4/9/2025	5/13/2025	3/25/2025	DISP-2671618	15	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2969060	22071423284	95939	4/10/2025	5/16/2025	3/25/2025	DISP-2671618	16	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2977497	22552229253	95939	4/10/2025	7/28/2025	3/25/2025	DISP-2671618	16	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3001979	22072837086	95939	4/15/2025	5/28/2025	3/25/2025	DISP-2671618	21	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026243	22653572517	95939	4/17/2025	6/5/2025	3/25/2025	DISP-2671618	23	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060513	22753636769	95939	4/22/2025	6/13/2025	3/25/2025	DISP-2671618	28	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091892	22353884451	95939	4/28/2025	5/30/2025	3/25/2025	DISP-2671618	34	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3216913	22755204307	95939	5/15/2025	6/22/2025	5/13/2025	DISP-2956806	2	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3278354	22555916421	95939	5/23/2025	7/23/2025	5/16/2025	DISP-2969060	7	\$9,843.83	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3456240	22757285248	95939	6/18/2025	7/28/2025	6/13/2025	DISP-3060513	5	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3458903	22557189096	95939	6/18/2025	7/29/2025	6/13/2025	DISP-3060513	5	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3514884	22356144464	95939	6/27/2025	9/3/2025	6/26/2025	DISP-3269945	1	\$8,400.94	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3527824	22257386838	95939	6/30/2025	8/4/2025	6/26/2025	DISP-3269945	4	\$8,400.94	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3527850	22658314815	95939	6/30/2025	8/19/2025	6/26/2025	DISP-3269945	4	\$17,315.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3529143	22257504137	95939	6/30/2025	9/4/2025	6/26/2025	DISP-3269945	4	\$8,400.94	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3664019	22078119415	95939	7/18/2025	9/5/2025	6/26/2025	DISP-3269945	22	\$7,608.45	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721282	22559775440	95939	7/28/2025	9/5/2025	7/26/2025	DISP-3456760	2	\$2,646.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3842810	22258010917	95939	8/13/2025	9/30/2025	8/4/2025	DISP-3527824	9	\$16,075.01	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-848371	22617903282	95941	12/20/2023	6/6/2024	9/29/2023	DISP-360121	82	\$5,366.55	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1491864	22414467926	95941	7/1/2024	8/5/2024	6/18/2024	DISP-1338651	13	\$6,409.90	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503693	22233439772	95941	7/4/2024	9/20/2024	6/18/2024	DISP-1338651	16	\$12,819.80	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1503773	22833577311	95941	7/4/2024	9/3/2024	6/18/2024	DISP-1338651	16	\$38,459.40	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-1612969	22235231286	95941	8/2/2024	9/18/2024	7/13/2024	DISP-1303796	20	\$38,459.40	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1669943	22052975163	95941	8/16/2024	10/8/2024	8/5/2024	DISP-1491864	11	\$12,819.80	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1733906	22335859346	95941	9/5/2024	10/17/2024	9/3/2024	DISP-1503773	2	\$32,049.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1734553	22336463461	95941	9/5/2024	10/17/2024	9/3/2024	DISP-1503773	2	\$38,459.40	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1761711	22436779390	95941	9/10/2024	11/23/2024	9/3/2024	DISP-1503773	7	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1760158	22137237027	95941	9/10/2024	10/22/2024	9/3/2024	DISP-1503773	7	\$19,229.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1817138	22736130233	95941	9/20/2024	11/15/2024	9/18/2024	DISP-1612969	2	\$11,179.35	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1825342	22336104061	95941	9/23/2024	11/19/2024	9/20/2024	DISP-1503693	3	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826149	22738652771	95941	9/23/2024	10/24/2024	9/20/2024	DISP-1503693	3	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1826545	22417111938	95941	9/23/2024	10/25/2024	9/20/2024	DISP-1503693	3	\$57,689.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851702	22539693367	95941	9/27/2024	11/22/2024	9/20/2024	DISP-1503693	7	\$73,984.68	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1898575	22840424174	95941	10/7/2024	2/24/2025	9/20/2024	DISP-1503693	17	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1994529	22141311388	95941	10/29/2024	12/6/2024	10/25/2024	DISP-1826545	4	\$22,358.70	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024426	22241247150	95941	11/4/2024	12/18/2024	10/25/2024	DISP-1826545	10	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2053083	22742624416	95941	11/7/2024	12/31/2024	10/25/2024	DISP-1826545	13	\$12,330.78	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2152716	22843530575	95941	11/25/2024	1/16/2025	11/23/2024	DISP-1761711	2	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2162924	22643758561	95941	11/26/2024	1/16/2025	11/25/2024	DISP-1898543	1	\$49,323.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2182602	22844079297	95941	11/29/2024	1/15/2025	11/25/2024	DISP-1898543	4	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237424	22644607831	95941	12/10/2024	4/21/2025	12/6/2024	DISP-1994529	4	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237436	22443823892	95941	12/10/2024	1/30/2025	12/6/2024	DISP-1994529	4	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237936	22844586127	95941	12/10/2024	1/30/2025	12/6/2024	DISP-1994529	4	\$36,992.84	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2253787	22836855749	95941	12/13/2024	1/14/2025	12/6/2024	DISP-1994529	7	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2317350	22844586126	95941	12/26/2024	2/4/2025	12/18/2024	DISP-2024426	8	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2323762	22645904596	95941	12/27/2024	2/6/2025	12/18/2024	DISP-2024426	9	\$98,646.24	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2355865	22646295587	95941	1/3/2025	1/20/2025	12/31/2024	DISP-2053083	3	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2356136	22646186697	95941	1/3/2025	1/23/2025	12/31/2024	DISP-2053083	3	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2375318	22846164385	95941	1/7/2025	1/23/2025	12/31/2024	DISP-2053083	7	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2411989	22846296920	95941	1/14/2025	2/13/2025	12/31/2024	DISP-2053083	14	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412160	22647134173	95941	1/14/2025	2/6/2025	12/31/2024	DISP-2053083	14	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412164	22747047938	95941	1/14/2025	2/6/2025	12/31/2024	DISP-2053083	14	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2412185	22847113443	95941	1/14/2025	2/13/2025	12/31/2024	DISP-2053083	14	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419626	22444489677	95941	1/15/2025	2/10/2025	1/14/2025	DISP-2253787	1	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419716	22846636199	95941	1/15/2025	2/13/2025	1/14/2025	DISP-2253787	1	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419610	22844522770	95941	1/15/2025	2/25/2025	1/14/2025	DISP-2253787	1	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2419708	22847256641	95941	1/15/2025	2/26/2025	1/14/2025	DISP-2253787	1	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2356136			
DISP-2465722	22547350965	95941	1/27/2025	2/14/2025	1/23/2025	DISP-2375318	4	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2356136			
DISP-2465732	22647903058	95941	1/27/2025	2/14/2025	1/23/2025	DISP-2375318	4	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2529620	22246304477	95941	2/5/2025	2/21/2025	2/4/2025	DISP-2317350	1	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2536968	22148279392	95941	2/6/2025	2/21/2025	2/4/2025	DISP-2317350	2	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2465722			
DISP-2607919	22548727476	95941	2/19/2025	3/10/2025	2/14/2025	DISP-2465732	5	\$49,323.12	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2465722			
DISP-2608245	22348592484	95941	2/19/2025	3/6/2025	2/14/2025	DISP-2465732	5	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2465722			
DISP-2608286	22247923915	95941	2/19/2025	6/19/2025	2/14/2025	DISP-2465732	5	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2529620			
DISP-2626973	22068564348	95941	2/22/2025	3/10/2025	2/21/2025	DISP-2536968	1	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2529620			
DISP-2626984	22149163232	95941	2/22/2025	3/11/2025	2/21/2025	DISP-2536968	1	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2670525	22650002761	95941	2/28/2025	3/25/2025	2/26/2025	DISP-2419708	2	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671606	22249869117	95941	2/28/2025	3/28/2025	2/26/2025	DISP-2419708	2	\$24,661.56	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2671621	22650130924	95941	2/28/2025	3/23/2025	2/26/2025	DISP-2419708	2	\$36,992.34	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685087	22069858988	95941	3/3/2025	3/25/2025	2/26/2025	DISP-2419708	5	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685235	22850114802	95941	3/3/2025	3/20/2025	2/26/2025	DISP-2419708	5	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2685245	22064731364	95941	3/3/2025	3/21/2025	2/26/2025	DISP-2419708	5	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2748620	22550706698	95941	3/12/2025	4/7/2025	3/11/2025	DISP-2626984	1	\$12,330.78	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
								DISP-2670525			
DISP-2847167	22551342875	95941	3/26/2025	4/29/2025	3/25/2025	DISP-2685087	1	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2890174	22251956203	95941	3/31/2025	4/30/2025	3/28/2025	DISP-2671606	3	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956595	22553455042	95941	4/9/2025	5/12/2025	4/7/2025	DISP-2748620	2	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2956577	22652708365	95941	4/9/2025	5/7/2025	4/7/2025	DISP-2748620	2	\$49,323.12	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

DISP No.	Claim Number	Code	Initiation Date	Determination Date	90-Day Start	DISP Triggering 90-Day	Days Between	Award (excl. fees)	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3007305	22553455043	95941	4/15/2025	5/16/2025	4/7/2025	DISP-2748620	8	\$24,661.56	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026241	22653572517	95941	4/17/2025	5/17/2025	4/7/2025	DISP-2748620	10	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3091877	22353884451	95941	4/28/2025	7/7/2025	4/7/2025	DISP-2748620	21	\$24,661.56	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3269941	22455209987	95941	5/22/2025	7/24/2025	5/17/2025	DISP-3026241	5	\$933.10	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3277950	22555916421	95941	5/23/2025	7/23/2025	5/17/2025	DISP-3026241	6	\$40,000.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-3457521	22757285248	95941	6/18/2025	8/7/2025	6/12/2025	DISP-3060502	6	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3457635	22557189096	95941	6/18/2025	7/28/2025	6/12/2025	DISP-3060502	6	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3513660	22356144464	95941	6/27/2025	8/5/2025	6/22/2025	DISP-3216909	5	\$8,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3529065	22257386838	95941	6/30/2025	9/4/2025	6/27/2025	DISP-3313463	3	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Provider Resources, Inc.
DISP-3528869	22257504137	95941	6/30/2025	8/1/2025	6/27/2025	DISP-3313463	3	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3663508	22078119415	95941	7/18/2025	10/15/2025	7/7/2025	DISP-3091877	11	\$2,400.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721525	22559775440	95941	7/28/2025	9/5/2025	7/27/2025	DISP-3459293	1	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3844107	22077531117	95941	8/13/2025	10/3/2025	8/7/2025	DISP-3457521	6	\$16,000.00	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization
DISP-2109526	22443235302	95955	11/19/2024	4/8/2025	9/19/2024	DISP-1503754	61	\$7,309.58	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-2237947	22342490541	95955	12/10/2024	1/30/2025	9/19/2024	DISP-1503754	82	\$8,599.50	BROMEDICON, LLC	HIGHMARK	EdiPhy Advisors, L.L.C.
DISP-3277944	22075139592	95955	5/23/2025	7/23/2025	4/29/2025	DISP-2845680	24	\$7,309.58	BROMEDICON, LLC	HIGHMARK	Island Peer Review Organization

EXHIBIT C

DISP No.	Claim Number	Code	Initiation Date	Determination Date	Award	Prevailing Party	Non-Prevailing Party	Certified IDR Entity
DISP-3837523	22077531117	92653	08/13/2025	09/12/2025	\$637.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3836626	22258010917	95717	08/13/2025	09/24/2025	\$70.27	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3879208	22361306513	95717	08/19/2025	11/17/2025	\$3,450.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4054504	22462325784	95720	09/11/2025	10/08/2025	\$26,653.32	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4152569	22763195633	95861	09/25/2025	10/16/2025	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3722110	22559775440	95868	07/28/2025	09/05/2025	\$3,619.33	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4461177	22365586186	95868	11/04/2025	11/26/2025	\$5,100.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3878874	22761527960	95870	08/19/2025	10/03/2025	\$10,200.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4203260	22080688063	95886	10/02/2025	10/24/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4022121	22361630511	95886	09/08/2025	11/12/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4052655	22562560966	95886	09/11/2025	11/21/2025	\$1,132.20	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4162031	22563127650	95886	09/26/2025	11/25/2025	\$566.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4164166	22563127650	95907	09/26/2025	10/25/2025	\$6,120.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3664015	22078119415	95937	07/18/2025	09/05/2025	\$557.10	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721960	22559775440	95937	07/28/2025	09/24/2025	\$619.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3924438	22461748815	95937	08/25/2025	10/03/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4020667	22361630511	95937	09/08/2025	10/03/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4202600	22080688063	95937	10/02/2025	11/06/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3841346	22077531117	95937	08/13/2025	11/14/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3879225	22761527960	95937	08/19/2025	11/25/2025	\$6,332.50	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060503	22753636769	95938	04/22/2025	05/29/2025	\$8,746.30	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528425	22257386838	95938	06/30/2025	08/01/2025	\$7,312.66	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4052152	22562560966	95938	09/11/2025	10/03/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4202626	22080688063	95938	10/02/2025	11/04/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4021919	22361630511	95938	09/08/2025	11/12/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4339998	22265100116	95938	10/21/2025	11/25/2025	\$11,900.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026243	22653572517	95939	04/17/2025	06/05/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3060513	22753636769	95939	04/22/2025	06/13/2025	\$9,843.83	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721282	22559775440	95939	07/28/2025	09/05/2025	\$2,646.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4020991	22361630511	95939	09/08/2025	10/06/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-4202263	22080688063	95939	10/02/2025	11/20/2025	\$17,850.01	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-1851702	22539693367	95941	09/27/2024	11/22/2024	\$73,984.68	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-2024426	22241247150	95941	11/04/2024	12/18/2024	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3026241	22653572517	95941	04/17/2025	05/17/2025	\$36,992.34	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3528869	22257504137	95941	06/30/2025	08/01/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3721525	22559775440	95941	07/28/2025	09/05/2025	\$16,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3663508	22078119415	95941	07/18/2025	10/15/2025	\$2,400.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.
DISP-3923993	22461748815	95941	08/25/2025	10/24/2025	\$32,000.00	BROMEDICON, LLC	HIGHMARK	C2C Innovative Solutions, Inc.

**Note: Several of these disputes were also ineligible for violation of the 90-day cooling off period.

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

Highmark, Inc.

(b) County of Residence of First Listed Plaintiff Allegheny County, PA
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)

William J. Sheridan, Reed Smith LLP
225 Fifth Ave, Pittsburgh, PA 15222, 412-288-7282

DEFENDANTS

Bromedicon, LLC and HaloMD, LLC

County of Residence of First Listed Defendant Montgomery County, PA
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF
THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff ☒ 3 Federal Question (U.S. Government Not a Party)
- ☐ 2 U.S. Government Defendant ☐ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|----------------------------|----------------------------|---|----------------------------|----------------------------|
| Citizen of This State | ☐ 1 | ☐ 1 | Incorporated or Principal Place of Business In This State | ☐ 4 | ☐ 4 |
| Citizen of Another State | ☐ 2 | ☐ 2 | Incorporated and Principal Place of Business In Another State | ☐ 5 | ☐ 5 |
| Citizen or Subject of a Foreign Country | ☐ 3 | ☐ 3 | Foreign Nation | ☐ 6 | ☐ 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)Click here for: [Nature of Suit Code Descriptions.](#)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
☐ 110 Insurance ☐ 120 Marine ☐ 130 Miller Act ☐ 140 Negotiable Instrument ☐ 150 Recovery of Overpayment & Enforcement of Judgment ☐ 151 Medicare Act ☐ 152 Recovery of Defaulted Student Loans (Excludes Veterans) ☐ 153 Recovery of Overpayment of Veteran's Benefits ☐ 160 Stockholders' Suits ☐ 190 Other Contract ☐ 195 Contract Product Liability ☐ 196 Franchise	PERSONAL INJURY ☐ 310 Airplane ☐ 315 Airplane Product Liability ☐ 320 Assault, Libel & Slander ☐ 330 Federal Employers' Liability ☐ 340 Marine ☐ 345 Marine Product Liability ☐ 350 Motor Vehicle ☐ 355 Motor Vehicle Product Liability ☐ 360 Other Personal Injury ☐ 362 Personal Injury - Medical Malpractice PERSONAL INJURY ☐ 365 Personal Injury - Product Liability ☐ 367 Health Care/Pharmaceutical Personal Injury Product Liability ☐ 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY ☐ 370 Other Fraud ☐ 371 Truth in Lending ☐ 380 Other Personal Property Damage ☐ 385 Property Damage Product Liability	☐ 625 Drug Related Seizure of Property 21 USC 881 ☐ 690 Other LABOR ☐ 710 Fair Labor Standards Act ☐ 720 Labor/Management Relations ☐ 740 Railway Labor Act ☐ 751 Family and Medical Leave Act ☐ 790 Other Labor Litigation ☐ 791 Employee Retirement Income Security Act IMMIGRATION ☐ 462 Naturalization Application ☐ 465 Other Immigration Actions	☐ 422 Appeal 28 USC 158 ☐ 423 Withdrawal 28 USC 157 PROPERTY RIGHTS ☐ 820 Copyrights ☐ 830 Patent ☐ 835 Patent - Abbreviated New Drug Application ☐ 840 Trademark ☐ 880 Defend Trade Secrets Act of 2016 SOCIAL SECURITY ☐ 861 HIA (1395ff) ☐ 862 Black Lung (923) ☐ 863 DIWC/DIWW (405(g)) ☐ 864 SSID Title XVI ☐ 865 RSI (405(g)) FEDERAL TAX SUITS ☐ 870 Taxes (U.S. Plaintiff or Defendant) ☐ 871 IRS—Third Party 26 USC 7609	☐ 375 False Claims Act ☐ 376 Qui Tam (31 USC 3729(a)) ☐ 400 State Reapportionment ☐ 410 Antitrust ☐ 430 Banks and Banking ☐ 450 Commerce ☐ 460 Deportation ☐ 470 Racketeer Influenced and Corrupt Organizations ☐ 480 Consumer Credit (15 USC 1681 or 1692) ☐ 485 Telephone Consumer Protection Act ☐ 490 Cable/Sat TV ☐ 850 Securities/Commodities/Exchange ☒ 890 Other Statutory Actions ☐ 891 Agricultural Acts ☐ 893 Environmental Matters ☐ 895 Freedom of Information Act ☐ 896 Arbitration ☐ 899 Administrative Procedure Act/Review or Appeal of Agency Decision ☐ 950 Constitutionality of State Statutes
REAL PROPERTY ☐ 210 Land Condemnation ☐ 220 Foreclosure ☐ 230 Rent Lease & Ejectment ☐ 240 Torts to Land ☐ 245 Tort Product Liability ☐ 290 All Other Real Property	CIVIL RIGHTS ☐ 440 Other Civil Rights ☐ 441 Voting ☐ 442 Employment ☐ 443 Housing/Accommodations ☐ 445 Amer. w/Disabilities - Employment ☐ 446 Amer. w/Disabilities - Other ☐ 448 Education PRISONER PETITIONS Habeas Corpus: ☐ 463 Alien Detainee ☐ 510 Motions to Vacate Sentence ☐ 530 General ☐ 535 Death Penalty Other: ☐ 540 Mandamus & Other ☐ 550 Civil Rights ☐ 555 Prison Condition ☐ 560 Civil Detainee - Conditions of Confinement			

V. ORIGIN (Place an "X" in One Box Only)

- ☒ 1 Original Proceeding ☐ 2 Removed from State Court ☐ 3 Remanded from Appellate Court ☐ 4 Reinstated or Reopened ☐ 5 Transferred from Another District (specify) ☐ 6 Multidistrict Litigation - Transfer ☐ 8 Multidistrict Litigation - Direct File

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
42 U.S.C. § 300gg-111(c)(5)(E) and 9 U.S.C. § 10(a)(1) through (4)

Brief description of cause:

This action involves claims arising under the No Surprises Act and other tort, statutory, and equitable claims.

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. **DEMAND \$**

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED CASE(S) IF ANY

(See instructions):

JUDGE

DOCKET NUMBER

6/1/2026

s/William J. Sheridan

DATE

SIGNATURE OF ATTORNEY OF RECORD

FOR OFFICE USE ONLY

RECEIPT # _____ AMOUNT _____ APPLYING IFP _____ JUDGE _____ MAG. JUDGE _____

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority for Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. The JS 44, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I. (a) Plaintiffs/Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify the agency and then the official, giving both name and title.
 - (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.) **ERIE CALENDAR** – If cause of action arose in the counties of *Crawford, Elk, Erie, Forest, McKean, Venango or Warren, OR any plaintiff or defendant resides in one of said counties. JOHNSTOWN CALENDAR* – If cause of action arose in the counties of *Bedford, Blair, Cambria, Clearfield or Somerset OR any plaintiff or defendant resides in one of said counties.*
 - (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below. **(1) UNITED STATES GOVERNMENT PLAINTIFF** - Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. **(2) UNITED STATES GOVERNMENT DEFENDANT** - When the plaintiff is suing the United States, its officers, or agencies, place an "X" in this box. **(3) FEDERAL QUESTION** - This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked. **(4) DIVERSITY (OF CITIZENSHIP)** - This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: [Nature of Suit Code Descriptions](#).
- V. Origin.** Place an "X" in one of the seven boxes. **(1) ORIGINAL PROCEEDING** - Cases which originate in the United States district courts. **(2) REMOVED FROM STATE COURT** - Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. **(3) REMANDED FROM APPELLATE COURT** - Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date. **(4) REINSTATED OR REOPENED** - Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date. **(5) TRANSFERRED FROM ANOTHER DISTRICT** - For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers. **(6) MULTIDISTRICT LITIGATION – TRANSFER** - Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. **(8) MULTIDISTRICT LITIGATION – DIRECT FILE** - Check this box when a multidistrict case is filed in the same district as the Master MDL docket. **PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7.** Origin Code 7 was used for historical records and is no longer relevant due to changes in statute.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service. Upon commencing a civil action that is eligible to be placed on the Johnstown or Erie docket pursuant to Local Civil Rule 3 and which is a Designated Civil Action, **the following statement must be included in the "Brief description of the cause" in Section VI.** (Cause of Action) of the Civil Cover Sheet (Form JS-44): **"This case seeks to bar or mandate governmental policies or state or federal actions of statewide or nationwide impact, by declaratory judgment and/or any form of injunctive relief."** If the action seeks to **(1)** bar or mandate statewide enforcement of a state law, including a rule, regulation, policy or order of the executive branch or a state agency, whether by declaratory judgment and/or any form of injunctive relief; or **(2)** seeks to bar or mandate nationwide enforcement of a federal law, including a rule, regulation, policy, or order of the executive branch or a federal agency, whether by declaratory judgment and/or any form of injunctive relief this language should be included pursuant to **Administrative Order 2024-09.**
- VII. Requested in Complaint. CLASS ACTION** - Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P. Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction. **JURY DEMAND** - Check the appropriate box to indicate whether a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases. **CIVIL** - Civil cases are deemed related when a case filed relates to property included in another suit or involves the same issues of fact or it grows out of the same transactions as another suit or involves the validity or infringement of a patent involved in another suit **HABEAS CORPUS & CIVIL RIGHTS** - All habeas corpus petitions filed by the same individual shall be deemed related. All pro se Civil Rights actions by the same individual shall be deemed related.

Date and Attorney Signature. Date and sign the civil cover sheet.

AO 440 (Rev. 06/12) Summons in a Civil Action

UNITED STATES DISTRICT COURT

for the

Western District of Pennsylvania

HIGHMARK, INC.

Plaintiff(s)

V.

BROMEDICON, LLC and HALOMD, LLC,

Defendant(s)

Civil Action No. 2:26-cv-1175

SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)*

Bromedicon, LLC
Capitol Corporate Services, Inc.
125 Locust Street
Harrisburg, PA 17101

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are: William J. Sheridan

William J. Sheridan
Reed Smith LLP
Reed Smith Centre
225 Fifth Avenue
Pittsburgh, PA 15222
Telephone: (412) 288-7282

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. 2:26-cv-1175

PROOF OF SERVICE*(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* _____
 was received by me on *(date)* _____ .

☐ I personally served the summons on the individual at *(place)* _____
 _____ on *(date)* _____ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
 _____, a person of suitable age and discretion who resides there,
 on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
 designated by law to accept service of process on behalf of *(name of organization)* _____
 _____ on *(date)* _____ ; or

☐ I returned the summons unexecuted because _____ ; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ 0.00 .

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc:

for the

HIGHMARK, INC.

Plaintiff(s)

V.

BROMEDICON, LLC and HALOMD, LLC,

Defendant(s)

Civil Action No. 2:26-cv-1175

To: *(Defendant's name and address)*

HaloMD, LLC
Capitol Corporate Services, Inc
108 Lakeland Ave
Dover, DE 19901

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are: William J. Sheridan

William J. Sheridan
Reed Smith LLP
Reed Smith Centre
225 Fifth Avenue
Pittsburgh, PA 15222
Telephone: (412) 288-7282

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. 2:26-cv-1175

PROOF OF SERVICE*(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* _____
 was received by me on *(date)* _____ .

☐ I personally served the summons on the individual at *(place)* _____
 _____ on *(date)* _____ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
 _____, a person of suitable age and discretion who resides there,
 on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
 designated by law to accept service of process on behalf of *(name of organization)* _____
 _____ on *(date)* _____ ; or

☐ I returned the summons unexecuted because _____ ; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ 0.00 .

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc: